{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor'''
|-
|style="background-color:#F0F0F0"|[[File:Headshot Cowan.jpg|frameless|upright=0.3|center]]
|<big>[[User:Andrewc072|Andrew J. Cowan, MD]]<br>Seattle, WA</big><br>[https://www.linkedin.com/in/andrew-cowan-63b3a130/ LinkedIn]
|-
|}
''Are you looking for a regimen but can't find it here? It is possible that we've moved it to the [[Multiple_myeloma_-_historical|historical regimens page]]. If you still can't find it, please let us know so we can add it!''.
<br><big>'''Note: due to its size/complexity, the multiple myeloma page has been split into three sub-pages:'''
*[[Multiple_myeloma,_induction|Induction (transplant eligible and ineligible)]]
*[[Multiple_myeloma,_consolidation_and_maintenance|First-line consolidation and maintenance]]
*Relapsed/refractory, including subsequent consolidation and maintenance [''this page'']
</big>
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}
{{#lst:Multiple myeloma|guidelines}}
<section begin=rrmm />
=Relapsed or refractory, randomized data=

==Bortezomib monotherapy {{#subobject:eadacb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 1 mg/m<sup>2</sup>, 21-day cycle x 8 {{#subobject:77fac1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2004.05188.x/full Jagannath et al. 2004 (CREST)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|Bortezomib +/- Dexamethasone
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.12198/full Petrucci et al. 2013 (RETRIEVE)]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
''Note: RETRIEVE was a re-treatment trial; the dose used was the same as in the initial treatment (1.0 or 1.3 mg/m<sup>2</sup>).''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11

'''21-day cycle for 8 cycles'''
====Subsequent treatment====
*CREST: Patients with PD after 2 cycles or SD after 4 cycles could escalate to [[#Bortezomib_.26_Dexamethasone_2|bortezomib & dexamethasone]]

===Variant #2, 1.3 mg/m<sup>2</sup>, 21-day cycle x 8 (IV) {{#subobject:cd7b63|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2004.05188.x/full Jagannath et al. 2004 (CREST)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|Low-dose Bortezomib +/- Dexamethasone
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa043445 Richardson et al. 2005 (APEX)]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#Dexamethasone_monotherapy_3|High-dose dexamethasone]]
|style="background-color:#91cf60"|Seems to have superior OS (*)
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70081-X/fulltext Moreau et al. 2011 (MMY-3021)]
|style="background-color:#1a9851"|Phase III (C)
|Subcutaneous Bortezomib +/- Dexamethasone
|style="background-color:#eeee01"|Non-inferior ORR
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.27745 White et al. 2012 (AMBER)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|Bortezomib & Bevacizumab
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.12198/full Petrucci et al. 2013 (RETRIEVE)]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737504/ Orlowski et al. 2015]
|style="background-color:#1a9851"|Randomized Phase II (C)
|Bortezomib & Siltuximab
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: RETRIEVE was a re-treatment trial; the dose used was the same as in the initial treatment (1.0 or 1.3 mg/m<sup>2</sup>).''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11

====Supportive medications====
*[[:Category:Bisphosphonates|Bisphosphonate]] IV therapy once every 3 to 4 weeks unless contraindicated

'''21-day cycle for 8 cycles (see note)'''
====Subsequent treatment====
*CREST: Patients with PD after 2 cycles or SD after 4 cycles could escalate to [[#Bortezomib_.26_Dexamethasone_2|bortezomib & dexamethasone]]
*APEX: [[#Bortezomib_monotherapy_2|Bortezomib consolidation]]
*MMY-3021: Patients with suboptimal response after 4 cycles could escalate to [[#Bortezomib_.26_Dexamethasone_2|bortezomib & dexamethasone]]; patients who were "evolving" towards CR after 8 cycles could receive 2 additional cycles
*Orlowski et al. 2015: [[#Bortezomib_monotherapy_3|Bortezomib maintenance]]

===Variant #3, 1.3 mg/m<sup>2</sup>, 21-day cycle x 8 (SC) {{#subobject:16fb4f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70081-X/fulltext Moreau et al. 2011 (MMY-3021)]
|style="background-color:#1a9851"|Phase III (E)
|Intravenous Bortezomib +/- Dexamethasone
|style="background-color:#eeee01"|Non-inferior ORR
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11
**Subcutaneous injections are 2.5 mg/mL (3.5 mg bortezomib reconstituted in 1.4 mL NS)
**SC injections are in the thighs or abdomen, with injection sites rotated between proximal/distal right/left thigh and upper/lower right/left abdominal quadrants 

====Supportive medications====
*[[:Category:Bisphosphonates|Bisphosphonates]] "according to established guidelines"

'''21-day cycle for 8 cycles (see note)'''
====Subsequent treatment====
*Patients with suboptimal response after 4 cycles could escalate to [[#Bortezomib_.26_Dexamethasone|bortezomib & dexamethasone]]; patients who were "evolving" towards CR after 8 cycles could receive 2 additional cycles

===Variant #4, indefinite 21-day cycles {{#subobject:e26d0e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa030288 Richardson et al. 2003 (SUMMIT)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://jco.ascopubs.org/content/25/25/3892.long Orlowski et al. 2007]
|style="background-color:#1a9851"|Phase III (C)
|[[#Bortezomib_.26_Doxorubicin_liposomal|Bortezomib & Doxorubicin liposomal]]
|style="background-color:#d73027"|Inferior TTP
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07409.x/full Mikhael et al. 2008]
|style="background-color:#91cf61"|Phase IIIb
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70398-X/fulltext Dimopoulos et al. 2013 (VANTAGE 088)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Bortezomib_.26_Vorinostat|Bortezomib & Vorinostat]]
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|}
''Note: SUMMIT and Mikhael et al. 2008 specified a total of 8 cycles, but those who were deriving clinical benefit could continue beyond this.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11

'''21-day cycles (see note)'''
====Subsequent treatment====
*SUMMIT & Mikhael et al. 2008: patients with PD after 2 cycles or SD after 4 cycles could escalate to [[#Bortezomib_.26_Dexamethasone|bortezomib & dexamethasone]]

===Variant #5, 1.6 mg/m<sup>2</sup>, 35-day cycle x 10 {{#subobject:59c4b8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.23606/full Hainsworth et al. 2008]
|style="background-color:#91cf61"|Phase II
|-
|}

====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.6 mg/m<sup>2</sup> IV bolus once per day on days 1, 8, 15, 22

'''35-day cycle for up to 10 cycles'''

===References===
# '''SUMMIT:''' Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26;348(26):2609-17. [https://www.nejm.org/doi/full/10.1056/NEJMoa030288 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12826635 PubMed]
## '''Subgroup analysis:''' Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC; SUMMIT/CREST Investigators. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006 Jul;91(7):929-34. [http://www.haematologica.org/content/91/7/929.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16818280 PubMed] 
## '''Subgroup analysis:''' Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Cowan JM, Anderson KC. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007 Jan;21(1):151-7. Epub 2006 Nov 9. [https://www.nature.com/articles/2404442 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17096017 PubMed]
# '''CREST:''' Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004 Oct;127(2):165-72. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2004.05188.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15461622 PubMed]
## '''Subgroup Analysis:''' Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC; SUMMIT/CREST Investigators. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006 Jul;91(7):929-34. [http://www.haematologica.org/content/91/7/929.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16818280 PubMed] 
## '''Update:''' Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine DL, Anderson KC. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008 Nov;143(4):537-40. Epub 2008 Sep 6. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07359.x/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18783399 PubMed]
# '''APEX:''' Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005 Jun 16;352(24):2487-98. [https://www.nejm.org/doi/full/10.1056/NEJMoa043445 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15958804 PubMed]
## '''Subgroup analysis:''' Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Cowan JM, Anderson KC. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007 Jan;21(1):151-7. Epub 2006 Nov 9. [https://www.nature.com/articles/2404442 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17096017 PubMed]
## '''Update:''' Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San Miguel J, Bladé J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007 Nov 15;110(10):3557-60. Epub 2007 Aug 9. [http://www.bloodjournal.org/content/110/10/3557.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17690257 PubMed]
# Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007 Sep 1;25(25):3892-901. Epub 2007 Aug 6. [http://jco.ascopubs.org/content/25/25/3892.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17679727 PubMed]
## '''Update:''' Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Xiu L, Cakana A, Parekh T, San-Miguel JF. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer. 2016 Jul 1;122(13):2050-6. Epub 2016 May 18. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.30026/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27191689 PubMed]
# Hainsworth JD, Spigel DR, Barton J, Farley C, Schreeder M, Hon J, Greco FA. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer. 2008 Aug 15;113(4):765-71. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.23606/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18543319 PubMed]
# Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, Petrucci MT, Musto P, Komarnicki M, Stewart AK. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol. 2009 Jan;144(2):169-75. Epub 2008 Nov 19. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07409.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19036114 PubMed]
# '''MMY-3021:''' Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011 May;12(5):431-40. Epub 2011 Apr 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70081-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21507715 PubMed]
## '''Update:''' Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de Velde H, Feng H, Cakana A, Deraedt W, Moreau P. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012 Dec;97(12):1925-8. Epub 2012 Jun 11. [http://www.haematologica.org/content/97/12/1925.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685287/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22689676 PubMed]
## '''Subgroup analysis:''' Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Rekhtman G, Masliak Z, Robak P, Esseltine DL, Feng H, Deraedt W, van de Velde H, Arnulf B. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. Haematologica. 2015 May;100(5):e207-10. Epub 2015 Jan 16. [http://www.haematologica.org/content/100/5/e207.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420234/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25596270 PubMed]
# '''AMBER:''' White D, Kassim A, Bhaskar B, Yi J, Wamstad K, Paton VE. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer. 2013 Jan 15;119(2):339-47. Epub 2012 Jul 18. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.27745 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22811009 PubMed]
# '''RETRIEVE:''' Petrucci MT, Giraldo P, Corradini P, Teixeira A, Dimopoulos MA, Blau IW, Drach J, Angermund R, Allietta N, Broer E, Mitchell V, Bladé J. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol. 2013 Mar;160(5):649-59. Epub 2013 Jan 7. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12198/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23293914 PubMed]
# '''VANTAGE 088:''' Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013 Oct;14(11):1129-1140. Epub 2013 Sep 19. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70398-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24055414 PubMed]
# Orlowski RZ, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, Goranova-Marinova V, Dimopoulos MA, Cavenagh JD, Špička I, Maiolino A, Suvorov A, Bladé J, Samoylova O, Puchalski TA, Reddy M, Bandekar R, van de Velde H, Xie H, Rossi JF. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol. 2015 Jan;90(1):42-9. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737504/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25294016 PubMed]

==Bortezomib & Dexamethasone {{#subobject:899402|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BD: '''<u>B</u>'''ortezomib, '''<u>D</u>'''examethasone
<br>Bd: '''<u>B</u>'''ortezomib, low-dose '''<u>d</u>'''examethasone
<br>Bort-Dex: '''<u>Bort</u>'''ezomib, '''<u>Dex</u>'''amethasone
<br>Vd: '''<u>V</u>'''elcade (Bortezomib), low-dose '''<u>d</u>'''examethasone
<br>VD: '''<u>V</u>'''elcade (Bortezomib), '''<u>D</u>'''examethasone

===Variant #1, indefinite 21-day then 28-day cycles {{#subobject:a29ce5 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900953/ Jakubowiak et al. 2016 (CA204-009)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#EBd|EBd]]
|style="background-color:#fee08b"|Might have inferior PFS
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] as follows:
**Cycles 1 to 8: 1.3 mg/m<sup>2</sup> IV or SC once per day on days 1, 4, 8, 11
**Cycle 9 onwards: 1.3 mg/m<sup>2</sup> IV or SC once per day on days 1, 8, 15
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 to 8: 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
**Cycle 9 onwards: 20 mg PO once per day on days 1, 2, 8, 9, 15, 16

'''21-day cycle for 8 cycles, then 28-day cycles'''

===Variant #2, SC 21-day cycles (8 total) {{#subobject:c5b78f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70081-X/fulltext Moreau et al. 2011 (MMY-3021)]
|style="background-color:#1a9851"|Phase III (E)
|IV Bort-Dex
|style="background-color:#eeee01"|Non-inferior ORR
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1606038 Palumbo et al. 2016 (CASTOR)]
|style="background-color:#1a9851"|Phase III (C)
|[[#DVd|DVd]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
====Preceding treatment====
*MMY-3021: [[#Bortezomib_monotherapy|Bortezomib]] x 4
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12

'''21-day cycle for 8 cycles (see note)'''

''In '''MMY-3021''', patients who were "evolving" towards CR after 8 cycles could receive 2 additional cycles.''

===Variant #3, 21-day followed by 42-day cycles (12 total) {{#subobject:c68433|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext San-Miguel et al. 2014 (PANORAMA 1)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Bortezomib.2C_Dexamethasone.2C_Panobinostat|Bortezomib, Dexamethasone, Panobinostat]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
====Chemotherapy, Phase 1====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12

'''21-day cycle for 8 cycles'''

''Patients who had clinical benefit per the modified European Group for Blood and Marrow Transplantation [EBMT] criteria on day 1 of cycle 8 proceeded to phase 2 treatment:''

====Chemotherapy, Phase 2====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 8, 22, 29
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1, 2, 8, 9, 22, 23, 29, 30

'''42-day cycle for 4 cycles'''

===Variant #4, 21-day cycles, response-adapted {{#subobject:47b011|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492844/ Hjorth et al. 2012 (NMSG 17/07)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Thal-Dex|Thal-Dex]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3729908/ Dimopoulos et al. 2013 (CR013165)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|Not evaluable
|style="background-color:#d3d3d3"|
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12

====Supportive medications====
*"Antithrombotic prophylaxis and [[Acyclovir (Zovirax)|acyclovir]] prophylaxis were not mandatory according to the study protocol but used routinely in an increasing proportion of participating centers during the study period."

'''21-day cycles until progression or best response, which would then be followed by 1 to 2 additional cycles'''

===Variant #5, IV 21-day cycles (8 total) {{#subobject:5d8a03|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2004.05188.x/full Jagannath et al. 2004 (CREST)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|Low-dose Bort-Dex
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70081-X/fulltext Moreau et al. 2011 (MMY-3021)]
|style="background-color:#1a9851"|Phase III (C)
|SC Bort-Dex
|style="background-color:#eeee01"|Non-inferior ORR
|-
|[https://link.springer.com/article/10.1007%2Fs00277-017-3065-z Kropff et al. 2017 (CR015247)]
|style="background-color:#1a9851"|Phase III (C)
|[[#VDC|VCD]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Preceding treatment====
*CREST: [[#Bortezomib_monotherapy|Bortezomib]] x 2 to 4 cycles
*MMY-3021: [[#Bortezomib_monotherapy|Bortezomib]] x 4
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12 

'''21-day cycle for 8 cycles (see note)'''

''In '''MMY-3021''', patients who were "evolving" towards CR after 8 cycles could receive 2 additional cycles.''

===Variant #6, low-dose IV 21-day cycles (8 total) {{#subobject:823e44|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2004.05188.x/full Jagannath et al. 2004 (CREST)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|Standard-dose Bort-Dex
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Preceding treatment====
*[[#Bortezomib_monotherapy|Bortezomib]] x 2 to 4 cycles
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12 

'''21-day cycle for 8 cycles'''

===Variant #7, IV indefinite 21-day cycles {{#subobject:0e7bc2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa030288 Richardson et al. 2003 (SUMMIT)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#8c6bb1" |RR: 35%
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07409.x/full Mikhael et al. 2008 (MMY-3001)]
|style="background-color:#91cf61"|Phase IIIb
| style="background-color:#d3d3d3" |
| style="background-color:#bfd3e6" |ORR: 67%
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00464-7/fulltext Dimopoulos et al. 2015 (ENDEAVOR)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carfilzomib_.26_Dexamethasone|Kd]]
| style="background-color:#d73027" |Inferior OS (*)
|-
|}
''Note: SUMMIT & MMY-3001 specified a total of 8 cycles, but those who were deriving clinical benefit could continue beyond this. Efficacy for ENDEAVOR based on the 2017 update.''
====Preceding treatment====
*SUMMIT & MMY-3001: [[#Bortezomib_monotherapy|Bortezomib]] x 2 to 4 cycles
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 20 mg IV or PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12 

'''21-day cycles'''

===Variant #8, SC indefinite 21-day cycles {{#subobject:6696bc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00464-7/fulltext Dimopoulos et al. 2015 (ENDEAVOR)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carfilzomib_.26_Dexamethasone|Kd]]
| style="background-color:#d73027" |Inferior OS (*)
|-
|}
''Note: efficacy based on the 2017 update.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 20 mg IV or PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12 

'''21-day cycles'''

===Variant #9, indefinite 35-day cycles {{#subobject:ed7a2d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ar.iiarjournals.org/content/31/6/2297.long Fukushima et al. 2011]
|style="background-color:#91cf61"|Phase II
| style="background-color:#e0ecf4" |ORR: 77%
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22
*[[Dexamethasone (Decadron)]] 20 mg IV or PO once per day on days 1, 2, 8, 9, 15, 16, 22, 23

'''35-day cycles until CR or indefinitely'''

===References===
# '''SUMMIT:''' Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26;348(26):2609-17. [https://www.nejm.org/doi/full/10.1056/NEJMoa030288 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12826635 PubMed]
## '''Subgroup analysis:''' Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC; SUMMIT/CREST Investigators. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006 Jul;91(7):929-34. [http://www.haematologica.org/content/91/7/929.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16818280 PubMed] 
## '''Subgroup analysis:''' Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Cowan JM, Anderson KC. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007 Jan;21(1):151-7. Epub 2006 Nov 9. [https://www.nature.com/articles/2404442 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17096017 PubMed]
# '''CREST:''' Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004 Oct;127(2):165-72. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2004.05188.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15461622 PubMed]
## '''Subgroup Analysis:''' Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC; SUMMIT/CREST Investigators. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006 Jul;91(7):929-34. [http://www.haematologica.org/content/91/7/929.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16818280 PubMed] 
## '''Update:''' Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine DL, Anderson KC. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008 Nov;143(4):537-40. Epub 2008 Sep 6. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07359.x/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18783399 PubMed]
# '''MMY-3001:''' Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, Petrucci MT, Musto P, Komarnicki M, Stewart AK. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol. 2009 Jan;144(2):169-75. Epub 2008 Nov 19. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07409.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19036114 PubMed]
# '''MMY-3021:''' Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011 May;12(5):431-40. Epub 2011 Apr 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70081-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21507715 PubMed]
## '''Update:''' Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de Velde H, Feng H, Cakana A, Deraedt W, Moreau P. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012 Dec;97(12):1925-8. Epub 2012 Jun 11. [http://www.haematologica.org/content/97/12/1925.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685287/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22689676 PubMed]
## '''Subgroup analysis:''' Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Rekhtman G, Masliak Z, Robak P, Esseltine DL, Feng H, Deraedt W, van de Velde H, Arnulf B. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. Haematologica. 2015 May;100(5):e207-10. Epub 2015 Jan 16. [http://www.haematologica.org/content/100/5/e207.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420234/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25596270 PubMed]
# Fukushima T, Nakamura T, Iwao H, Nakajima A, Miki M, Sato T, Sakai T, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Nakajima H, Motoo Y, Umehara H. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events. Anticancer Res. 2011 Jun;31(6):2297-302. [http://ar.iiarjournals.org/content/31/6/2297.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21737655 PubMed]
# '''NMSG 17/07:''' Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A; Nordic Myeloma Study Group (NMSG). Thalidomide and dexamethasone vs bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol. 2012 Jun;88(6):485-96. Epub 2012 Mar 30. [https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-0609.2012.01775.x link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492844/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22404182 PubMed]
# '''CR013165:''' Dimopoulos MA, Beksac M, Benboubker L, Roddie H, Allietta N, Broer E, Couturier C, Mazier MA, Angermund R, Facon T. Phase 2 study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica. 2013 Aug;98(8):1264-72. Epub 2013 May 28. [http://www.haematologica.org/content/98/8/1264.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3729908/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23716559 PubMed]
<!-- Presented in abstract form at the American Society of Hematology Annual Meeting, Atlanta, GA, December 8-11, 2012. -->
# '''PANORAMA 1:''' San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1195-206. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25242045 PubMed]
## '''Subgroup analysis:''' Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016 Feb 11;127(6):713-21. Epub 2015 Dec 2. [http://www.bloodjournal.org/content/127/6/713.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760132/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26631116 PubMed]
## '''Update:''' San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F, Richardson PG. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 2016 Nov;3(11):e506-e515. Epub 2016 Oct 14. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30147-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27751707 PubMed]
# '''ENDEAVOR:''' Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016 Jan;17(1):27-38. Epub 2015 Dec 5. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00464-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26671818 PubMed]
## '''Subgroup analysis:''' Chng WJ, Goldschmidt H, Dimopoulos MA, Moreau P, Joshua D, Palumbo A, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Feng S, Aggarwal S, Hájek R. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2017 Jun;31(6):1368-1374. Epub 2016 Dec 27. [https://www.nature.com/articles/leu2016390 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467042/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28025582 PubMed]
## '''Update:''' Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1327-1337. Epub 2017 Aug 23. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30578-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28843768 PubMed]
# '''CA204-009:''' Jakubowiak A, Offidani M, Pégourie B, De La Rubia J, Garderet L, Laribi K, Bosi A, Marasca R, Laubach J, Mohrbacher A, Carella AM, Singhal AK, Tsao LC, Lynch M, Bleickardt E, Jou YM, Robbins M, Palumbo A. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016 Jun 9;127(23):2833-40. Epub 2016 Apr 18. [http://www.bloodjournal.org/content/127/23/2833.long link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900953/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27091875 PubMed]
<!-- # ASCO 2016 Abstract LBA4 -->
# '''CASTOR:''' Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66. [https://www.nejm.org/doi/full/10.1056/NEJMoa1606038 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1606038/suppl_file/nejmoa1606038_appendix.pdf link to supplementary appendix] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27557302 PubMed]
## '''Update:''' Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018 Dec;103(12):2079-87. Epub 2018 Sep 20. [http://www.haematologica.org/content/103/12/2079 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30237264 PubMed]
# '''CR015247:''' Kropff M, Vogel M, Bisping G, Schlag R, Weide R, Knauf W, Fiechtner H, Kojouharoff G, Kremers S, Berdel WE. Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study. Ann Hematol. 2017 Nov;96(11):1857-1866. Epub 2017 Sep 14. [https://link.springer.com/article/10.1007%2Fs00277-017-3065-z link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28905189 PubMed]

==Bortezomib, Dexamethasone, Panobinostat {{#subobject:PYR1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:PYV1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/122/14/2331.full Richardson et al. 2013 (PANORAMA 2)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext San-Miguel et al. 2014 (PANORAMA 1)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Bortezomib_.26_Dexamethasone|Bortezomib & Dexamethasone]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Chemotherapy, phase 1====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
*[[Panobinostat (Farydak)]] 20 mg PO once per day on days 1, 3, 5, 8, 10, 12

'''21-day cycle for 8 cycles'''

''Patients who had clinical benefit per the modified European Group for Blood and Marrow Transplantation [EBMT] criteria on day 1 of cycle 8 proceeded to phase 2 treatment:''

====Chemotherapy, phase 2====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 8, 22, 29
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1, 2, 8, 9, 22, 23, 29, 30
*[[Panobinostat (Farydak)]] 20 mg PO once per day on days 1, 3, 5, 8, 10, 12, 22, 24, 26, 29, 31, 33

'''42-day cycle for 4 cycles (PANORAMA 1) or indefinitely (PANORAMA 2)'''

===References===
# '''PANORAMA 2:''' Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley CS, Lonial S. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013 Oct 3;122(14):2331-7. [http://www.bloodjournal.org/content/122/14/2331.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23950178 PubMed]
<!-- Presented in abstract form at the American Society of Hematology Annual Meeting, Atlanta, GA, December 8-11, 2012. -->
# '''PANORAMA 1:''' San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1195-206. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25242045 PubMed]
## '''Subgroup analysis:''' Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016 Feb 11;127(6):713-21. Epub 2015 Dec 2. [http://www.bloodjournal.org/content/127/6/713.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760132/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26631116 PubMed]
## '''Update:''' San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F, Richardson PG. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 2016 Nov;3(11):e506-e515. Epub 2016 Oct 14. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30147-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27751707 PubMed]

==Bortezomib & Doxorubicin liposomal {{#subobject:2a0373|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:bef7d6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/25/25/3892.long Orlowski et al. 2007]
|style="background-color:#1a9851"|Phase III (E)
|[[#Bortezomib_monotherapy|Bortezomib]]
|style="background-color:#1a9850"|Superior TTP
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11
*[[Pegylated liposomal doxorubicin (Doxil)]] 30 mg/m<sup>2</sup> IV over at least 1 hour once on day 4, '''given second'''

====Supportive medications====
*[[:Category:Bisphosphonates|Bisphosphonates]] were used according to established guidelines

'''21-day cycle for 8 or more cycles'''

===References===
# Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007 Sep 1;25(25):3892-901. Epub 2007 Aug 6. [http://jco.ascopubs.org/content/25/25/3892.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17679727 PubMed]
## '''Update:''' Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Xiu L, Cakana A, Parekh T, San-Miguel JF. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer. 2016 Jul 1;122(13):2050-6. Epub 2016 May 18. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.30026/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27191689 PubMed]

==Bortezomib & Vorinostat {{#subobject:2a5b7f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:a5c93b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70398-X/fulltext Dimopoulos et al. 2013 (VANTAGE 088)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Bortezomib_monotherapy|Bortezomib]]
|style="background-color:#91cf60"|Seems to have superior PFS
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11
*[[Vorinostat (Zolinza)]] 400 mg PO once per day on days 1 to 14

'''21-day cycles'''

===References===
# '''VANTAGE 088:''' Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013 Oct;14(11):1129-1140. Epub 2013 Sep 19. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70398-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24055414 PubMed]

==Carfilzomib monotherapy {{#subobject:36c1ce|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 20/27 dosing, variant #1 {{#subobject:270a70|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220126/ Hájek et al. 2016 (FOCUS)]
|style="background-color:#1a9851"|Phase III (E)
|1. [[#Cyclophosphamide_.26_Dexamethasone|Cyclophosphamide & Dexamethasone]]<br> 2. [[#Cyclophosphamide_.26_Prednisone|CP]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: this is an experimental arm that did not meet its primary endpoint; included here because other variants of this regimen have ORRs greater than 20%.''
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] as follows:
**Cycle 1: 20 mg/m<sup>2</sup> IV over 10 minutes once per day on days 1 & 2, then 27 mg/m<sup>2</sup> IV over 10 minutes once per day on days 8, 9, 15, 16
**Cycles 2 to 9: 27 mg/m<sup>2</sup> IV over 10 minutes once per day on days 1, 2, 8, 9, 15, 16
**Cycle 10 onwards: 27 mg/m<sup>2</sup> IV over 10 minutes once per day on days 1, 2, 15, 16

====Supportive medications====
*IV and PO hydration required for cycle 1
*[[Dexamethasone (Decadron)]] 4 mg IV or PO prior to each cycle 1 dose
*[[Ciprofloxacin (Cipro)]] 500 mg PO once per day during cycle 1

'''28-day cycles'''

===Variant #2, 20/27 dosing, variant #2 {{#subobject:51e1ba|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785611/ Watanabe et al. 2016]
|style="background-color:#91cf61"|Phase I/II
| style="background-color:#88419d; color:white |ORR: 22.5%
|-
|}
''This is the maximum predetermined dose, there was no MTD; ORR is reported for the phase II portion.''
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] as follows:
**Cycle 1: 20 mg/m<sup>2</sup> IV once per day on days 1 & 2, then 27 mg/m<sup>2</sup> IV once per day on days 8, 9, 15, 16
**Cycle 2 onwards: 27 mg/m<sup>2</sup> IV once per day on days 1, 2, 8, 9, 15, 16

====Supportive medications====
*IV and PO hydration required for cycle 1, then as needed
*[[Dexamethasone (Decadron)]] 4 mg IV or PO prior to each cycle 1 dose, then as needed
*Prophylactic antibiotics (not specified) in cycle 1
*[[Acyclovir (Zovirax)]] for patients with history of herpes infection, in cycle 1

'''28-day cycles'''

===Variant #3, 20/56 dosing {{#subobject:2563a9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624439/ Lendvai et al. 2014]
|style="background-color:#91cf61"|Phase II
| style="background-color:#9ebcda" |ORR: 55%
|-
|}
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] as follows:
**Cycle 1: 20 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 2, then 56 mg/m<sup>2</sup> IV over 30 minutes once per day on days 8, 9, 15, 16
**Cycle 2 onwards: 56 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 2, 8, 9, 15, 16

====Supportive medications====
*Normal saline pre- and post-hydration, tapered over subsequent cycles (see text for details)
*[[Dexamethasone (Decadron)]] 8 mg (route not specified) mandated with each cycle 1 dose, then optional
*[[Palonosetron (Aloxi)]] 250 mcg (route not specified) mandated with each cycle 1 dose, then optional
*[[Acyclovir (Zovirax)]] 400 mg PO once per day

'''28-day cycles'''
===Variant #4, 20/27 dosing, with BSA cap {{#subobject:166b4f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123327/ Vij et al. 2012a (PX-171-004 bortezomib-naive)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#9ebcda" |ORR: 42-52%
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123387/ Siegel et al. 2012 (PX-171-003-A1)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#88419d; color:white |ORR: 24%
|-
|}
''Note: Neither Vij et al. 2012a nor Siegel et al. 2012 specify that carfilzomib is capped at a body surface area of 2.2 m<sup>2</sup>, but the package insert specifies that: "The dose is calculated using the patient’s actual body surface area at baseline. Patients with a body surface area greater than 2.2 m<sup>2</sup> should receive a dose based upon a body surface area of 2.2 m<sup>2</sup>. Dose adjustments do not need to be made for weight changes of less than or equal to 20%."''
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] as follows:
**Cycle 1: 20 mg/m<sup>2</sup> (body surface area capped at 2.2 m<sup>2</sup>) IV over 2 to 10 minutes once per day on days 1, 2, 8, 9, 15, 16
**Cycle 2 onwards: 27 mg/m<sup>2</sup> (body surface area capped at 2.2 m<sup>2</sup>) IV over 2 to 10 minutes once per day on days 1, 2, 8, 9, 15, 16

====Supportive medications====
*[[Dexamethasone (Decadron)]] 4 mg IV or PO before all doses in cycle 1 (Vij et al. 2012a also administered one dose of dexamethasone 4 mg before the first increased dose of carfilzomib 27 mg/m<sup>2</sup>). Restart dexamethasone premedication if patients experience infusion reactions: "fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina."
*"All patients were to receive oral and intravenous fluids before dosing to assure adequate hydration."

====Dose modifications====
*"Carfilzomib was withheld for grade 3 or 4 hematologic or nonhematologic toxicities and resumed at reduced doses of 15 mg/m<sup>2</sup> in cycle 1 or 20 mg/m<sup>2</sup> in cycle 2 and above on resolution."

'''28-day cycle for up to 12 cycles'''

===Variant #5, 20/20 dosing {{#subobject:0b775a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2012.09232.x/full Vij et al. 2012b (PX-171-004 bortezomib-exposed)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#88419d; color:white |ORR: 17%
|-
|[http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(12)00148-6/fulltext Jagannath et al. 2012 (PX-171-003-A0)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#88419d; color:white |ORR: 17%
|-
|}
''Note: Patients enrolled in PX-171-004 could continue therapy beyond 12 cycles on PX-171-010; results of this extension study have not been published, to our knowledge.''
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] 20 mg/m<sup>2</sup> IV once per day on days 1, 2, 8, 9, 15, 16

'''28-day cycle for up to 12 cycles (see note)'''

===Variant #6, 15/20/27 dosing, for renal impairment {{#subobject:bdffd3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
| style="background-color:#88419d; color:white |ORR: 17%
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3740399/ Badros et al. 2013 (PX-171-005)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#8c6bb1" |ORR: 25.5%
|-
|}
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] as follows:
**Cycle 1: 15 mg/m<sup>2</sup> IV over 2 to 10 minutes once per day on days 1, 2, 8, 9, 15, 16
**Cycle 2: 20 mg/m<sup>2</sup> IV over 2 to 10 minutes once per day on days 1, 2, 8, 9, 15, 16
**Cycle 3 onwards: 27 mg/m<sup>2</sup> IV over 2 to 10 minutes once per day on days 1, 2, 8, 9, 15, 16

====Supportive medications====
*[[Dexamethasone (Decadron)]] 4 mg (route not specified) before all doses in cycle 1. Continue dexamethasone premedication if patients experience "treatment-related fever, chills, and/or dyspnea."
*"All patients were "required to be well hydrated."

'''28-day cycle for 12 cycles or longer if deriving clinical benefit'''
====Subsequent treatment====
*Patients with less than PR after 2 cycles or less than CR after 4 cycles were allowed to escalate to [[#Carfilzomib_.26_Dexamethasone|carfilzomib & dexamethasone]]

===References===
# '''PX-171-004 bortezomib-naive:''' Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012 Jun 14;119(24):5661-70. Epub 2012 May 3. [http://www.bloodjournal.org/content/119/24/5661.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123327/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22555973 PubMed]
# '''PX-171-004 bortezomib-exposed:''' Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012 Sep;158(6):739-48. Epub 2012 Jul 30. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2012.09232.x/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22845873 PubMed]
# '''PX-171-003-A0:''' Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):310-8. [http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(12)00148-6/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23040437 PubMed]
# '''PX-171-003-A1:''' Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012 Oct 4;120(14):2817-25. Epub 2012 Jul 25. [http://www.bloodjournal.org/content/120/14/2817.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123387/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22833546 PubMed] '''Pivotal trial for accelerated FDA approval'''
## '''Subgroup analysis:''' Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013 Dec;27(12):2351-6. Epub 2013 May 14. [https://www.nature.com/leu/journal/v27/n12/full/leu2013152a.html link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865533/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23670297 PubMed]
# '''PX-171-005:''' Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013 Aug;27(8):1707-14. Epub 2013 Jan 31. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3740399/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23364621 PubMed]
# Lendvai N, Hilden P, Devlin S, Landau H, Hassoun H, Lesokhin AM, Tsakos I, Redling K, Koehne G, Chung DJ, Schaffer WL, Giralt SA. A phase 2 single-center study of carfilzomib 56 mg/m<sup>2</sup> with or without low-dose dexamethasone in relapsed multiple myeloma. Blood. 2014 Aug 7;124(6):899-906. Epub 2014 Jun 24. [http://www.bloodjournal.org/content/124/6/899 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624439/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24963043 PubMed]
# Watanabe T, Tobinai K, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K, Izutsu K, Ishikawa T, Shumiya Y, Kashihara T, Iida S. A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma. Br J Haematol. 2016 Mar;172(5):745-56. Epub 2016 Jan 5. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13900/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785611/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26732066 PubMed]
# '''FOCUS:''' Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017 Jan;31(1):107-114. Epub 2016 Jun 24. [https://www.nature.com/leu/journal/v31/n1/full/leu2016176a.html link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220126/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27416912 PubMed]

==Carfilzomib & Dexamethasone {{#subobject:0823d6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Kd: '''<u>K</u>'''yprolis (Carfilzomib) & low-dose '''<u>d</u>'''examethasone
===Variant #1, 20/27 {{#subobject:9a649a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext Moreau et al. 2018 (ARROW)]
|style="background-color:#1a9851"|Phase III (C)
|Weekly Kd
| style="background-color:#d73027" |Inferior PFS
|-
|}
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] as follows:
**Cycle 1: 20 mg/m<sup>2</sup> IV over 10 minutes once per day on days 1 & 2, then 27 mg/m<sup>2</sup> IV over 10 minutes once per day on days 8, 9, 15, 16
**Cycle 2 onwards: 27 mg/m<sup>2</sup> IV over 10 minutes once per day on days 1, 2, 8, 9, 15, 16
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 to 8: 40 mg IV or PO once per day on days 1, 8, 15, 22
**Cycle 10 onwards: 40 mg IV or PO once per day on days 1, 8, 15
 
'''28-day cycles'''

===Variant #2, 20/56 dosing {{#subobject:9bd940|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00464-7/fulltext Dimopoulos et al. 2015 (ENDEAVOR)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Bortezomib_.26_Dexamethasone|Vd]]
|style="background-color:#1a9850"|Superior OS (*)
|-
|}
''Note: efficacy based on the 2017 update.''
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] as follows:
**Cycle 1: 20 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 2, then 56 mg/m<sup>2</sup> IV over 30 minutes once per day on days 8, 9, 15, 16
**Cycle 2 onwards: 56 mg/m<sup>2</sup> IV once per day on days 1, 2, 8, 9, 15, 16
*[[Dexamethasone (Decadron)]] 20 mg IV or PO once per day on days 1, 2, 8, 9, 15, 16, 22, 23

'''28-day cycles'''

===Variant #3, 20/70 dosing (weekly) {{#subobject:5322cb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929927/ Berenson et al. 2016 (CHAMPION-1)]
|style="background-color:#91cf61"|Phase I/II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext Moreau et al. 2018 (ARROW)]
|style="background-color:#1a9851"|Phase III (E)
|Twice-weekly Kd
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] as follows:
**Cycle 1: 20 mg/m<sup>2</sup> IV over 30 minutes once on day 1, then 70 mg/m<sup>2</sup> IV over 30 minutes once per day on days 8 & 15
**Cycle 2 onwards: 70 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 to 8: 40 mg IV or PO once per day on days 1, 8, 15, 22
**Cycle 10 onwards: 40 mg IV or PO once per day on days 1, 8, 15
 
'''28-day cycles'''

===Variant #4, 27 dosing {{#subobject:2b988e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3740399/ Badros et al. 2013 (PX-171-005)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#Carfilzomib_monotherapy|Carfilzomib]] x 2 to 4 cycles (carfilzomib dose escalation attained during this period)
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] 27 mg/m<sup>2</sup> IV over 2 to 10 minutes once per day on days 1, 2, 8, 9, 15, 16
*[[Dexamethasone (Decadron)]] 20 mg (route not specified) once per day on days 1, 2, 8, 9, 15, 16, '''given first'''

'''28-day cycle for 12 cycles or longer if deriving clinical benefit'''

===References===
# '''PX-171-005:''' Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013 Aug;27(8):1707-14. Epub 2013 Jan 31. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3740399/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23364621 PubMed]
# '''ENDEAVOR:''' Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016 Jan;17(1):27-38. Epub 2015 Dec 5. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00464-7/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26671818 PubMed]
## '''Subgroup analysis:''' Chng WJ, Goldschmidt H, Dimopoulos MA, Moreau P, Joshua D, Palumbo A, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Feng S, Aggarwal S, Hájek R. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2017 Jun;31(6):1368-1374. Epub 2016 Dec 27. [https://www.nature.com/articles/leu2016390 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467042/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28025582 PubMed]
## '''Update:''' Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1327-1337. Epub 2017 Aug 23. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30578-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28843768 PubMed]
# '''CHAMPION-1:''' Berenson JR, Cartmell A, Bessudo A, Lyons RM, Harb W, Tzachanis D, Agajanian R, Boccia R, Coleman M, Moss RA, Rifkin RM, Patel P, Dixon S, Ou Y, Anderl J, Aggarwal S, Berdeja JG. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. 2016 Jun 30;127(26):3360-8. Epub 2016 May 12. [http://www.bloodjournal.org/content/127/26/3360.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929927/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27207788 PubMed]
# '''ARROW:''' Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, Stewart AK. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (ARROW): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018 Jul;19(7):953-964. Epub 2018 Jun 1. Erratum in: Lancet Oncol. 2018 Aug;19(8):e382. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29866475 PubMed]

==CRd (Carfilzomib) {{#subobject:dec1da|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CRd: '''<u>C</u>'''arfilzomib, '''<u>R</u>'''evlimid (Lenalidomide), low-dose '''<u>d</u>'''examethasone
<br>KRd: '''<u>K</u>'''yprolis (Carfilzomib), '''<u>R</u>'''evlimid (Lenalidomide), low-dose '''<u>d</u>'''examethasone

===Variant #1 {{#subobject:de433f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1411321 Stewart et al. 2014 (ASPIRE)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Rd|Rd]]
|style="background-color:#1a9850"|Superior OS (*)
|style="background-color:#1a9850"|Superior GHS/QoL
|-
|}
''Efficacy based on the 2018 update.''
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] as follows:
**Cycle 1: 20 mg/m<sup>2</sup> IV over 10 minutes once per day on days 1 & 2, then 27 mg/m<sup>2</sup> IV over 10 minutes once per day on days 8, 9, 15, 16
**Cycles 2 to 12: 27 mg/m<sup>2</sup> IV over 10 minutes once per day on days 1, 2, 8, 9, 15, 16
**Cycles 13 to 18: 27 mg/m<sup>2</sup> IV over 10 minutes once per day on days 1, 2, 15, 16
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22

====Supportive medications====
*[[Valacyclovir (Valtrex)]] (dose not specified) or equivalent [[:Category:Antivirals|antiviral]] while taking [[Lenalidomide (Revlimid)]]
*[[Aspirin]] (dose not specified) or other [[:Category:Anticoagulants|anticoagulant]] or [[:Category:Antiplatelet_agents|antiplatelet]] medication such as [[Clopidogrel (Plavix)]], [[:Category:Low_molecular_weight_heparins|low-molecular-weight heparin]] or [[Warfarin (Coumadin)]] while taking [[Lenalidomide (Revlimid)]]
*[[:Category:Bisphosphonates|Bisphosphonates]] while taking [[Dexamethasone (Decadron)]]
*[[Lansoprazole (Prevacid)]] (dose not specified) or other [[:Category:Proton_pump_inhibitors|proton pump inhibitor]] while taking [[Dexamethasone (Decadron)]]
*A prophylactic antibiotic ([[Ciprofloxacin (Cipro)]], [[Amoxicillin]], [[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] are given as examples)

'''28-day cycle for 18 cycles'''
====Subsequent treatment====
*If no progression: RD maintenance

===Variant #2 {{#subobject:b40f55|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3814729/ Wang et al. 2013 (PX-171-006)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] as follows:
**Cycle 1: 20 mg/m<sup>2</sup> IV once per day on days 1 & 2, then 27 mg/m<sup>2</sup> IV once per day on days 8, 9, 15, 16
**Cycles 2 to 12: 27 mg/m<sup>2</sup> IV once per day on days 1, 2, 8, 9, 15, 16
**Cycles 13 to 18: 27 mg/m<sup>2</sup> IV once per day on days 1, 2, 15, 16
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22

'''28-day cycle for up to 18 cycles, longer duration allowed at discretion of investigator'''

''Patients with at least SD after 4 cycles received up to 12 cycles; patients with at least SD after 12 cycles received up to 18 cycles.''

===References===
# '''PX-171-006:''' Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood. 2013 Oct 31;122(18):3122-8. Epub 2013 Sep 6. [http://www.bloodjournal.org/content/122/18/3122.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3814729/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24014245 PubMed]
# '''ASPIRE:''' Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 8;372(2):142-52. Epub 2014 Dec 6. [https://www.nejm.org/doi/full/10.1056/NEJMoa1411321 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25482145 PubMed]
## '''Subgroup analysis:''' Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016 Sep 1;128(9):1174-80. Epub 2016 Jul 20. [http://www.bloodjournal.org/content/128/9/1174.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009511/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27439911 PubMed]
## '''HRQoL analysis:''' Stewart AK, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A. Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol. 2016 Nov 10;34(32):3921-3930. [http://ascopubs.org/doi/full/10.1200/JCO.2016.66.9648 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27601539 PubMed]
## '''Update:''' Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018 Mar 10;36(8):728-734. Epub 2018 Jan 17. [http://ascopubs.org/doi/full/10.1200/JCO.2017.76.5032 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29341834 PubMed]

==Cyclophosphamide & Dexamethasone {{#subobject:2c713a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:5a653e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220126/ Hájek et al. 2016 (FOCUS)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carfilzomib_monotherapy|Carfilzomib]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: cyclophosphamide was described as optional for the control arm but 95% of patients received it. To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 50 mg PO once per day
*[[Dexamethasone (Decadron)]] 6 mg PO once every other day

'''Continued indefinitely'''

===References===
# Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017 Jan;31(1):107-114. Epub 2016 Jun 24. [https://www.nature.com/leu/journal/v31/n1/full/leu2016176a.html link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220126/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27416912 PubMed]

==Cyclophosphamide & Prednisone {{#subobject:969973|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CP: '''<u>C</u>'''yclophosphamide & '''<u>P</u>'''rednisone
<br>CyPred: '''<u>Cy</u>'''clophosphamide & '''<u>Pred</u>'''nisone
===Variant #1 {{#subobject:bcd1ee|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220126/ Hájek et al. 2016 (FOCUS)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carfilzomib_monotherapy|Carfilzomib]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: cyclophosphamide was described as optional for the control arm but 95% of patients received it. To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 50 mg PO once per day
*[[Prednisone (Sterapred)]] 30 mg PO once every other day

'''Continued indefinitely'''

===Variant #2 {{#subobject:0a11f4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.sciencedirect.com/science/article/pii/S0300297701001401 de Weerdt et al. 2001]
|style="background-color:#91cf61"|Non-randomized
|-
|}
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 100 mg PO once per day
*[[Prednisone (Sterapred)]] 10 to 20 mg PO once per day

'''Continued indefinitely'''

===References===
# de Weerdt O, van de Donk NW, Veth G, Bloem AC, Hagenbeek A, Lokhorst HM. Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. Neth J Med. 2001 Aug;59(2):50-6. [https://www.sciencedirect.com/science/article/pii/S0300297701001401 link to SD article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11476912 PubMed]
# '''FOCUS:''' Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017 Jan;31(1):107-114. Epub 2016 Jun 24. [https://www.nature.com/leu/journal/v31/n1/full/leu2016176a.html link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220126/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27416912 PubMed]

==DRd {{#subobject:0e17f7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DRd: '''<u>D</u>'''aratumumab, '''<u>R</u>'''evlimid (Lenalidomide), low-dose '''<u>d</u>'''examethasone
===Regimen {{#subobject:5cbf82|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054695/ Plesner et al. 2016]
|style="background-color:#91cf61"|Phase I/II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1607751 Dimopoulos et al. 2016 (POLLUX)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Rd|Rd]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Chemotherapy====
*[[Daratumumab (Darzalex)]] as follows:
**Cycles 1 & 2: 16 mg/kg IV once per week
**Cycles 3 to 6: 16 mg/kg IV once every two weeks
**Cycle 7 onwards: 16 mg/kg IV once per cycle
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
**'''POLLUX:''' Patients with CrCl of 30 to 60 mL/min/1.73m<sup>2</sup> received 10 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22
**'''POLLUX:''' Patients older than 75 years or underweight (BMI less than 18.5) could receive 20 mg

'''28-day cycle for up to 24 months (Plesner et al. 2014) or indefinitely (POLLUX)'''

===References===
<!-- # '''Abstract:''' Torben Plesner, MD, Hendrik-Tobias Arkenau, MD, Henk M. Lokhorst, MD PhD, Peter Gimsing, MD, PhD, Jakub Krejcik, MD, Charlotte Lemech, MD, Monique C. Minnema, MD PhD, Ulrik Lassen, MD PhD, Jacob P. Laubach, MD, Tahamtan Ahmadi, MD, PhD, Howard Yeh, MD, Mary E Guckert, MSN, RN, Huaibao Feng, Nikolai Constantin Brun, MD PhD, Steen Lisby, Linda Basse, MD DMSc, Antonio Palumbo, MD. Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma. ASH 2014 Abstract 84. [https://ash.confex.com/ash/2014/webprogram/Paper74400.html link to abstract]. -->
# Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Laubach JP, Palumbo A, Lisby S, Basse L, Wang J, Sasser AK, Guckert ME, de Boer C, Khokhar NZ, Yeh H, Clemens PL, Ahmadi T, Lokhorst HM, Richardson PG. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood. 2016 Oct 6;128(14):1821-8. Epub 2016 Aug 16. [http://www.bloodjournal.org/content/128/14/1821.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054695/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27531679 PubMed]
# '''POLLUX:''' Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Oct 6;375(14):1319-1331. [https://www.nejm.org/doi/full/10.1056/NEJMoa1607751 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1607751/suppl_file/nejmoa1607751_protocol.pdf link to original protocol] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27705267 PubMed]
## '''Update:''' Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O' Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018 Dec;103(12):2088-96. Epub 2018 Sep 20. [https://www.ncbi.nlm.nih.gov/pubmed/30237262 PubMed]

==DVd {{#subobject:5770be|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DVd: '''<u>D</u>'''aratumumab, '''<u>V</u>'''elcade (Bortezomib), low-dose '''<u>d</u>'''examethasone

===Regimen {{#subobject:18a80b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1606038 Palumbo et al. 2016 (CASTOR)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Bortezomib_.26_Dexamethasone|Vd]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Chemotherapy====
*[[Daratumumab (Darzalex)]] as follows:
**Cycles 1 to 3: 16 mg/kg IV once per week 
**Cycles 4 to 8: 16 mg/kg IV once on day 1
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 20 mg IV or PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
**Can be dose-reduced to 20 mg IV or PO once per week for patients greater than 75 years, with BMI less than 18.5, or with previous side effects

'''21-day cycle for 8 cycles'''
====Subsequent treatment====
*[[#Daratumumab_monotherapy|Daratumumab maintenance]]

===References===
<!-- # ASCO 2016 Abstract LBA4 -->
# '''CASTOR:''' Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66. [https://www.nejm.org/doi/full/10.1056/NEJMoa1606038 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1606038/suppl_file/nejmoa1606038_appendix.pdf link to supplementary appendix] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27557302 PubMed]
## '''Update:''' Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018 Dec;103(12):2079-87. Epub 2018 Sep 20. [http://www.haematologica.org/content/103/12/2079 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30237264 PubMed]

==EBd {{#subobject:165bf3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EBd: '''<u>E</u>'''lotuzumab, '''<u>B</u>'''ortezomib, low-dose '''<u>d</u>'''examethasone
===Regimen {{#subobject:ad710b |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900953/ Jakubowiak et al. 2016]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Bortezomib_.26_Dexamethasone|Bd]]
|style="background-color:#d9ef8b"|Might have superior PFS
|-
|}
====Chemotherapy====
*[[Elotuzumab (Empliciti)]] as follows:
**Cycles 1 & 2: 10 mg/kg IV once per day on days 1, 8, 15 
**Cycles 3 to 8: 10 mg/kg IV once per day on days 1 & 11
**Cycle 9 onwards: 10 mg/kg IV once per day on days 1 & 15
*[[Bortezomib (Velcade)]] as follows:
**Cycles 1 to 8: 1.3 mg/m<sup>2</sup> IV or SC once per day on days 1, 4, 8, 11
**Cycle 9 onwards: 1.3 mg/m<sup>2</sup> IV or SC once per day on days 1, 8, 15
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 & 2: 
***20 mg PO once per day on days 2, 4, 5, 9, 11, 12
***8 mg PO 3 to 24 hours prior and 8 mg IV 45 minutes prior to [[Elotuzumab (Empliciti)]] on days 1, 8, 15
**Cycles 3 to 8: 
***20 mg PO once per day on days 2, 4, 5, 8, 9, 12
***8 mg PO 3 to 24 hours prior and 8 mg IV 45 minutes prior to [[Elotuzumab (Empliciti)]] on days 1 & 11
**Cycle 9 onwards: 
***20 mg PO once per day on days 2, 8, 9, 16
***8 mg PO 3 to 24 hours prior and 8 mg IV 45 minutes prior to [[Elotuzumab (Empliciti)]] on days 1 & 15

====Supportive medications====
*[[Diphenhydramine (Benadryl)]] 25 to 50 mg (route not specified) 30 to 90 minutes prior to [[Elotuzumab (Empliciti)]]
*[[Ranitidine (Zantac)]] 50 mg (route not specified) 30 to 90 minutes prior to [[Elotuzumab (Empliciti)]]
*[[Acetaminophen (Tylenol)]] 650 to 1000 mg PO 30 to 90 minutes prior to [[Elotuzumab (Empliciti)]]

'''21-day cycle for 8 cycles, then 28-day cycles'''

===References===
# Jakubowiak A, Offidani M, Pégourie B, De La Rubia J, Garderet L, Laribi K, Bosi A, Marasca R, Laubach J, Mohrbacher A, Carella AM, Singhal AK, Tsao LC, Lynch M, Bleickardt E, Jou YM, Robbins M, Palumbo A. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016 Jun 9;127(23):2833-40. Epub 2016 Apr 18. [http://www.bloodjournal.org/content/127/23/2833.long link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900953/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27091875 PubMed]

==ELd {{#subobject:b79daa |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ELd: '''<u>E</u>'''lotuzumab, '''<u>L</u>'''enalidomide, low-dose '''<u>d</u>'''examethasone
<br>ERd: '''<u>E</u>'''lotuzumab, '''<u>R</u>'''evlimid (Lenalidomide), low-dose '''<u>d</u>'''examethasone
===Variant #1, 10/25/40 {{#subobject:f2d044 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1505654 Lonial et al. 2015 (ELOQUENT-2)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Rd|Ld]]
|style="background-color:#91cf60"|Seems to have superior OS (*)
|-
|[http://jco.ascopubs.org/content/30/16/1953.long Lonial et al. 2012 (1703 Study)]
|style="background-color:#1a9851"|Randomized Phase Ib/II (E)
|Elotuzumab 20 mg, Lenalidomide, Dexamethasone
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: the complex dexamethasone instructions for '''ELOQUENT-2''' were not described in the abstract of '''Richardson et al. 2015'''. Efficacy reported for '''ELOQUENT-2''' is based on the 2017 update.''
====Chemotherapy====
*[[Elotuzumab (Empliciti)]] as follows:
**Cycles 1 & 2: 10 mg/kg IV once per day on days 1, 8, 15, 22 
**Cycle 3 onwards: 10 mg/kg IV once per day on days 1 & 15
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] 40 mg PO once per week on weeks without elotuzumab; 28 mg PO and 8 mg IV on days when [[Elotuzumab (Empliciti)]] is administered
**According to the elotuzumab package insert, the 28 mg PO dose should be given between 3 and 24 hours before elotuzumab; the 8 mg IV dose should be given 45 to 90 minutes before elotuzumab. 

====Supportive medications====
*[[Diphenhydramine (Benadryl)]] 25 to 50 mg (route not specified) or its equivalent 30 to 90 minutes prior to [[Elotuzumab (Empliciti)]]
*[[Ranitidine (Zantac)]] 50 mg (route not specified) or its equivalent 30 to 90 minutes prior to [[Elotuzumab (Empliciti)]]
*[[Acetaminophen (Tylenol)]] 650 to 1000 mg (route not specified) or its equivalent 30 to 90 minutes prior to [[Elotuzumab (Empliciti)]]
*"Thromboembolic prophylaxis (e.g., aspirin, low-molecular-weight heparin, or vitamin K antagonists) was administered according to institutional guidelines or at the discretion of the investigator."

'''28-day cycles'''

===Variant #2, 20/25/40 {{#subobject:949377|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/30/16/1953.long Lonial et al. 2012 (1703 Study)]
|style="background-color:#1a9851"|Randomized Phase Ib/II (E)
|Elotuzumab 10 mg, Lenalidomide, Dexamethasone
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Elotuzumab (Empliciti)]] as follows:
**Cycles 1 & 2: 20 mg/kg IV once per day on days 1, 8, 15, 22 
**Cycle 3 onwards: 20 mg/kg IV once per day on days 1 & 15
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] 40 mg PO once per week

'''28-day cycles'''

===References===
<!-- # '''Abstract:''' Richardson, Paul G., Jagannath, Sundar, Moreau, Philippe, Jakubowiak, Andrzej, Raab, Marc S, Facon, Thierry, Vij, Ravi, White, Darrell J., Reece, Donna, Benboubker, Lotfi, Zonder, Jeffrey A., Deng, Wei, Kroog, Glenn, Singhal, Anil K, Lonial, Sagar. A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results. ASH Annual Meeting Abstracts 2012 120: 202 --> 
# '''1703 Study:''' Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C, Singhal AK, Jagannath S. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012 Jun 1;30(16):1953-9. [http://jco.ascopubs.org/content/30/16/1953.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22547589 PubMed]
<!-- ## '''Abstract: Update:''' Paul G. Richardson, Sundar Jagannath, MD, Philippe Moreau, MD, Andrzej Jakubowiak, MD, PhD, Marc S Raab, MD, PhD, Thierry Facon, MD, Ravi Vij, MBBS, MD, Darrell White, MD, Donna E. Reece, MD, Lotfi Benboubker, MD, PhD, Jeffrey Zonder, MD, L. Claire Tsao, PhD, Kenneth C. Anderson, MD, Eric Bleickardt, MD, Anil K Singhal, MD and Sagar Lonial, MD. Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. ASH 2014 Abstract 302 [https://ash.confex.com/ash/2014/webprogram/Paper74278.html link to abstract] -->
## '''Update:''' Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, Vij R, White D, Reece DE, Benboubker L, Zonder J, Tsao LC, Anderson KC, Bleickardt E, Singhal AK, Lonial S; 1703 study investigators. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015 Dec;2(12):e516-27. Epub 2015 Nov 16. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(15)00197-0/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26686406 PubMed]
# '''ELOQUENT-2:''' Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015 Aug 13;373(7):621-31. [https://www.nejm.org/doi/full/10.1056/NEJMoa1505654 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26035255 PubMed]
## '''Update:''' Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017 Sep;178(6):896-905. Epub 2017 Jul 5. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14787/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28677826 PubMed]
## '''Update:''' Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018 Oct 15;124(20):4032-4043. Epub 2018 Sep 11. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.31680 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30204239 PubMed]

==Elo-Pom-dex {{#subobject:149a50 |Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Elo-Pom-dex: '''<u>Elo</u>'''tuzumab, '''<u>Pom</u>'''alidomide, low-dose '''<u>dex</u>'''amethasone
===Regimen {{#subobject:a22809 |Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1805762 Dimopoulos et al. 2018 (ELOQUENT-3)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Pomalidomide_.26_Dexamethasone|Pomalidomide & Dexamethasone]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Elotuzumab (Empliciti)]] as follows:
**Cycles 1 & 2: 10 mg/kg IV once per day on days 1, 8, 15, 22 
**Cycle 3 onwards: 20 mg/kg IV once on day 1
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] as follows:
**Up to 75 years: 40 mg PO once per week on weeks without elotuzumab; 28 mg PO and 8 mg IV on days when [[Elotuzumab (Empliciti)]] is administered
**Older than 75: 20 mg PO once per week on weeks without elotuzumab; 8 mg PO and 8 mg IV on days when [[Elotuzumab (Empliciti)]] is administered

====Supportive medications====
*[[Diphenhydramine (Benadryl)]] 25 to 50 mg (route not specified) or its equivalent 45 to 90 minutes prior to [[Elotuzumab (Empliciti)]]
*[[Ranitidine (Zantac)]] 50 mg (route not specified) or its equivalent 45 to 90 minutes prior to [[Elotuzumab (Empliciti)]]
*[[Acetaminophen (Tylenol)]] 650 to 1000 mg (route not specified) 45 to 90 minutes prior to [[Elotuzumab (Empliciti)]]
*"Thromboembolic prophylaxis was required "according to institutional guidelines or at the discretion of the investigator."

'''28-day cycles'''

===References===
# '''ELOQUENT-3:''' Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018 Nov 8;379(19):1811-1822. [https://www.nejm.org/doi/full/10.1056/NEJMoa1805762 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30403938 PubMed]

==IRd {{#subobject:PYR3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
IRd: '''<u>I</u>'''xazomib, '''<u>R</u>'''evlimid (Lenalidomide), low-dose '''<u>d</u>'''examethasone

===Regimen {{#subobject:PYV3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1516282 Moreau et al. 2016 (TOURMALINE-MM1)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Rd|Rd]]
|style="background-color:#1a9850"|Superior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500972/ Hou et al. 2017 (TOURMALINE-MM1 China Continuation)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Rd|Rd]]
|style="background-color:#1a9850"|Superior OS
|-
|}
====Chemotherapy====
*[[Ixazomib (Ninlaro)]] 4 mg PO once per day on days 1, 8, 15, taken at least one hour before or at least two hours after food
*[[Lenalidomide (Revlimid)]] as follows:
**Normal renal function: 25 mg PO once per day on days 1 to 21
**CrCl of less than or equal to 60 mL/min/1.73m<sup>2</sup> or less than or equal to 50 mL/min/1.73m<sup>2</sup> (depends on local practice): 10 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22

====Supportive medications====
*Thromboprophylaxis required 

'''28-day cycles'''

===References===
<!-- # Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014 Aug 14;124(7):1038-46. [http://www.bloodjournal.org/content/124/7/1038 link to original article][https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574453/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24920586 PubMed]
# '''Abstract:''' Philippe Moreau, MD, Tamás Masszi, MD, Norbert Grzasko, MD, PhD, Nizar J Bahlis, MD, Markus Hansson, Ludek Pour, MD, Irwindeep Sandhu, MD, Peter Ganly, BMBCh, PhD, Bartrum W Baker, MBChB, FRACP, FRCPA, Sharon Jackson, MBChB, FRACP, FRCPA, Anne-Marie Stoppa, MD, David R Simpson, MBChB, FRACP, FRCPA, Peter Gimsing, MD, DMSci, Antonio Palumbo, Laurent Garderet, MD, Michele Cavo, Shaji K. Kumar, MD, Cyrille Touzeau, MD, Francis Buadi, MD, Jacob P. Laubach, MD, Jianchang Lin, PhD, Deborah Berg, RN, MSN, Alessandra DiBacco, PhD, Ai-Min Hui, MD, PhD and Paul G. Richardson, MD. Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537). ASH Annual Meeting 2015 Abstract 727 [https://ash.confex.com/ash/2015/webprogram/Paper79829.html link to abstract] -->
# '''TOURMALINE-MM1:''' Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Apr 28;374(17):1621-1634. [https://www.nejm.org/doi/full/10.1056/NEJMoa1516282 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27119237 PubMed]
## '''Subgroup analysis:''' Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017 Dec 14;130(24):2610-2618. Epub 2017 Oct 20. [http://www.bloodjournal.org/content/130/24/2610.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29054911 PubMed]
# '''TOURMALINE-MM1 China Continuation:''' Hou J, Jin J, Xu Y, Wu D, Ke X, Zhou D, Lu J, Du X, Chen X, Li J, Liu J, Gupta N, Hanley MJ, Li H, Hua Z, Wang B, Zhang X, Wang H, van de Velde H, Richardson PG, Moreau P. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. J Hematol Oncol. 2017 Jul 6;10(1):137. [https://jhoonline.biomedcentral.com/articles/10.1186/s13045-017-0501-4 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500972/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28683766 PubMed]

==Ixazomib & Dexamethasone {{#subobject:af43a2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1 {{#subobject:55fb47|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558585/ Kumar et al. 2015]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114487/ Kumar et al. 2016]
|style="background-color:#1a9851"|Randomized Phase II (E)
|Ixazomib 4 mg & Dexamethasone
|style="background-color:#d9ef8b"|Might have superior ORR
|-
|}
====Chemotherapy====
*[[Ixazomib (Ninlaro)]] 5.5 mg PO once per day on days 1, 8, 15
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1, 2, 8, 9, 15, 16

====Supportive medications====
*Herpes zoster prophylaxis

'''28-day cycles''' 

===Variant #2 {{#subobject:0ec76c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114487/ Kumar et al. 2016]
|style="background-color:#1a9851"|Randomized Phase II (E)
|Ixazomib 5.5 mg & Dexamethasone
|style="background-color:#fee08b"|Might have inferior ORR
|-
|}
====Chemotherapy====
*[[Ixazomib (Ninlaro)]] 4 mg PO once per day on days 1, 8, 15
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1, 2, 8, 9, 15, 16

====Supportive medications====
*Herpes zoster prophylaxis

'''28-day cycles''' 

===References===
# Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 2015 Aug 14;5:e338. [https://www.nature.com/bcj/journal/v5/n8/full/bcj201560a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558585/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26275080 PubMed]
# Kumar SK, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F, Gertz MA, Bergsagel PL, Dispenzieri A, Thompson MA, Crawley J, Kapoor P, Mikhael J, Stewart K, Hayman SR, Hwa YL, Gonsalves W, Witzig TE, Ailawadhi S, Dingli D, Go RS, Lin Y, Rivera CE, Rajkumar SV, Lacy MQ. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood. 2016 Nov 17;128(20):2415-2422. [http://www.bloodjournal.org/content/128/20/2415.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114487/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27702799 PubMed]

==Lenalidomide monotherapy {{#subobject:ea18d8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:96b9ec|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895441/ Richardson et al. 2006]
|style="background-color:#1a9851"|Randomized Phase II (E)
|Lenalidomide 15 mg PO twice per day
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://www.bloodjournal.org/content/114/4/772.long Richardson et al. 2009]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|}
''This regimen is essentially of historical interest, as neither dosing of lenalidomide is in common use now.''
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 30 mg PO once per day on days 1 to 21

'''28-day cycles'''
====Subsequent treatment====
*Richardson et al. 2006: Patients with SD or progression after 2 cycles were escalated to [[#Rd_3|RD]]

===References===
# Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15;108(10):3458-64. Epub 2006 Jul 13. [http://www.bloodjournal.org/content/108/10/3458.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895441/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/16840727 PubMed]
# Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R, Kenvin L, Yu Z, Olesnyckyj M, Zeldis J, Knight R, Anderson KC. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood. 2009 Jul 23;114(4):772-8. Epub 2009 May 26. [http://www.bloodjournal.org/content/114/4/772.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19471019 PubMed]

==Pomalidomide & Dexamethasone {{#subobject:06b435|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PD: '''<u>P</u>'''omalidomide, '''<u>D</u>'''examethasone
<br>PomDex: '''<u>Pom</u>'''alidomide, '''<u>Dex</u>'''amethasone
<br>Pom + LoDEX: '''<u>Pom</u>'''alidomide, '''<u>Lo</u>'''w-dose '''<u>Dex</u>'''amethasone

===Variant #1, 4 mg 21/28 {{#subobject:ed2ee6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext San Miguel et al. 2013 (MM-003)]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#Dexamethasone_monotherapy_3|Dexamethasone]]
|style="background-color:#1a9850"|Superior OS (*)
|-
|[http://www.bloodjournal.org/content/121/11/1968.long Leleu et al. 2013 (IFM 2009-02)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|Pom-Dex (28/28)
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962162/ Richardson et al. 2014]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Pomalidomide_monotherapy|Pomalidomide]]
|style="background-color:#91cf60"|Seems to have superior PFS
|-
|[http://www.bloodjournal.org/content/125/9/1411.long Leleu et al. 2015 (IFM 2010-02)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://www.bloodjournal.org/content/127/21/2561.long Baz et al. 2016]
|style="background-color:#1a9851"|Randomized Phase I/II (C)
|[[#PomCyDex|PomCyDex]]
|style="background-color:#fc8d59"|Seems to have inferior ORR rate
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009959/ Dimopoulos et al. 2016 (STRATUS)]
|style="background-color:#91cf61"|Phase IIIb
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|}
''Note: efficacy reported for MM-003 is based on the 2015 update.''
====Chemotherapy====
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] as follows:
**Age less than or equal to 75: 40 mg PO once per day on days 1, 8, 15, 22
**Age greater than 75: 20 mg PO once per day on days 1, 8, 15, 22

====Supportive medications====
*San Miguel et al. 2013: Thromboprohpylaxis required. "Choice of thromboprophylaxis and use of myeloid and erythroid growth factors was left to the physician's discretion." 
*Leleu et al. 2013: Thromboprophylaxis "at the physician's discretion"
*Richardson et al. 2014: [[Aspirin]] 81 to 100 mg PO once per day unless contraindicated
*Baz et al. 2016: [[Aspirin]] 81 mg PO once per day unless contraindicated
*'''STRATUS''': Thromboprophylaxis with low-dose [[Aspirin]], [[:Category:Low_molecular_weight_heparins||LMWH]], or equivalent was required
*Leleu et al. 2013: [[Filgrastim (Neupogen) | G-CSF]] allowed beginning with cycle 2 and on

'''28-day cycles'''

===Variant #2, 4 mg continuous {{#subobject:306c08|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291492/ Lacy et al. 2011]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://www.bloodjournal.org/content/121/11/1968.long Leleu et al. 2013 (IFM 2009-02)]
|style="background-color:#1a9851"|Randomized phase II, >20 patients (E)
|Pom-Dex (21/28)
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 28
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22

====Supportive medications====
*Lacy et al. 2011: [[Aspirin]] 325 mg PO once per day
**[[:Category:Low_molecular_weight_heparins|low molecular weight heparin]] or [[Warfarin (Coumadin)]] could be substituted at physician discretion
*Leleu et al. 2013: Thromboprophylaxis "at the physician's discretion"
*Leleu et al. 2013: [[Filgrastim (Neupogen) | G-CSF]] allowed beginning with cycle 2 and on

'''28-day cycles'''

===Variant #3, 2 mg continuous {{#subobject:567775|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/27/30/5008.long Lacy et al. 2009]
|style="background-color:#91cf61"|Phase II
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2978257/ Lacy et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291492/ Lacy et al. 2011]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Pomalidomide (Pomalyst)]] 2 mg PO once per day on days 1 to 28
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22

====Supportive medications====
*[[Aspirin]] 325 mg PO once per day
**[[:Category:Low_molecular_weight_heparins|low molecular weight heparin]] or [[Warfarin (Coumadin)]] could be substituted at physician discretion

'''28-day cycles'''

===References===
# Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009 Oct 20;27(30):5008-14. Epub 2009 Aug 31. [http://jco.ascopubs.org/content/27/30/5008.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19720894 PubMed]
# Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV, Buadi F. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010 Nov;24(11):1934-9. Epub 2010 Sep 9. [https://www.nature.com/leu/journal/v24/n11/full/leu2010190a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2978257/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20827286 PubMed] 
# Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Laumann K, Mandrekar SJ, Reeder C, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011 Sep 15;118(11):2970-5. Epub 2011 Jun 20. [http://www.bloodjournal.org/content/118/11/2970.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291492/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21690557 PubMed]
# '''IFM 2009-02:''' Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, Mathiot C, Petillon MO, Macro M, Roussel M, Pegourie B, Kolb B, Stoppa AM, Hennache B, Bréchignac S, Meuleman N, Thielemans B, Garderet L, Royer B, Hulin C, Benboubker L, Decaux O, Escoffre-Barbe M, Michallet M, Caillot D, Fermand JP, Avet-Loiseau H, Facon T. Pomalidomide plus low dose dexamethasone is active and well tolerated in bortezomib and lenalidomide refractory multiple myeloma: IFM 2009-02. Blood. 2013 Mar 14;121(11):1968-1975. Epub 2013 Jan 14. [http://www.bloodjournal.org/content/121/11/1968.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23319574 PubMed]
# '''MM-003:''' San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Oct;14(11):1055-66. Epub 2013 Sep 3. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70380-2/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24007748 PubMed]
## '''Update:''' Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Spencer A, Knop S, Bahlis NJ, Renner C, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel JF. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica. 2015 Oct;100(10):1327-33. Epub 2015 Aug 6. [http://www.haematologica.org/content/100/10/1327.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591765/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26250580 PubMed]
# Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson K. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20;123(12):1826-32. Epub 2014 Jan 13. Erratum in: Blood. 2014 May 15;123(20):3208-9. [http://www.bloodjournal.org/content/123/12/1826.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962162/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24421329 PubMed]
# '''IFM 2010-02:''' Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, Arnulf B, Pegourie B, Kolb B, Stoppa AM, Brechiniac S, Marit G, Thielemans B, Onraed B, Mathiot C, Banos A, Lacotte L, Tiab M, Dib M, Fuzibet JG, Petillon MO, Rodon P, Wetterwald M, Royer B, Legros L, Benboubker L, Decaux O, Escoffre-Barbe M, Caillot D, Fermand JP, Moreau P, Attal M, Avet-Loiseau H, Facon T; Intergroupe Francophone du Myélome (IFM). Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. Blood. 2015 Feb 26;125(9):1411-7. Epub 2015 Jan 9. [http://www.bloodjournal.org/content/125/9/1411.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25575538 PubMed]
<!-- Presented in part at the annual meeting of the American Society of Hematology, San Francisco, CA, December 6-9, 2014. -->
# Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016 May 26;127(21):2561-8. Epub 2016 Mar 1. Erratum in: Blood. 2016 Jul 21;128(3):461. [http://www.bloodjournal.org/content/127/21/2561.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26932802 PubMed]
# '''STRATUS:''' Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel KC, Oriol A, Hansson M, Vacca A, Blanchard MJ, Goldschmidt H, Doyen C, Kaiser M, Petrini M, Anttila P, Cafro AM, Raymakers R, San-Miguel J, de Arriba F, Knop S, Röllig C, Ocio EM, Morgan G, Miller N, Simcock M, Peluso T, Herring J, Sternas L, Zaki MH, Moreau P. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016 Jul 28;128(4):497-503. Epub 2016 May 25. [http://www.bloodjournal.org/content/128/4/497.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009959/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27226434 PubMed]

==Pomalidomide monotherapy {{#subobject:0e409f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a946bf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962162/ Richardson et al. 2014]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#Pomalidomide_.26_Dexamethasone|POM+LoDEX (PD)]]
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21

====Supportive medications====
*[[Aspirin]] 81 to 100 mg PO once per day (unless contraindicated)

'''28-day cycles'''

===References===
# Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson K. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20;123(12):1826-32. Epub 2014 Jan 13. Erratum in: Blood. 2014 May 15;123(20):3208-9. [http://www.bloodjournal.org/content/123/12/1826.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962162/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24421329 PubMed]

==PomCyDex {{#subobject:e75204|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PomCyDex: '''<u>Pom</u>'''alidomide, '''<u>Cy</u>'''clophosphamide, '''<u>Dex</u>'''amethasone
<br>PCD: '''<u>P</u>'''omalidomide, '''<u>C</u>'''yclophosphamide, '''<u>D</u>'''examethasone
===Variant #1, 4/300/40 {{#subobject:d700f5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/132/24/2555.long Garderet et al. 2018 (IC 2013-05)]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21
*[[Cyclophosphamide (Cytoxan)]] 300 mg PO once per day on days 1, 8, 15, 22
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 to 4: 40 mg PO once per day on days 1 to 4, 15 to 18
**Cycle 5 onwards: 40 mg PO once per day on days 1, 8, 15, 22

'''28-day cycle for 4 to 9 cycles, depending on plan for transplant'''
====Subsequent treatment====
*Pomalidomide & Dexamethasone maintenance

===Variant #2, 4/400/40 {{#subobject:abacf6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/127/21/2561.long Baz et al. 2016]
|style="background-color:#1a9851"|Randomized Phase I/II (E)
|[[#Pomalidomide_.26_Dexamethasone|PomDex]]
|style="background-color:#91cf60"|Seems to have superior ORR rate
|-
|}
====Chemotherapy====
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21
*[[Cyclophosphamide (Cytoxan)]] 400 mg PO once per day on days 1, 8, 15
*[[Dexamethasone (Decadron)]] 40 mg (20 mg for patients greater than 75 years old) PO once per day on days 1, 8, 15, 22

====Supportive medications====
*[[Aspirin]] 81 mg PO once per day unless contraindicated

'''28-day cycles'''

===References===
<!-- Presented in part at the annual meeting of the American Society of Hematology, San Francisco, CA, December 6-9, 2014. -->
# Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016 May 26;127(21):2561-8. Epub 2016 Mar 1. Erratum in: Blood. 2016 Jul 21;128(3):461. [http://www.bloodjournal.org/content/127/21/2561.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26932802 PubMed]
# '''IC 2013-05:''' Garderet L, Kuhnowski F, Berge B, Roussel M, Escoffre-Barbe M, Lafon I, Facon T, Leleu X, Karlin L, Perrot A, Moreau P, Marit G, Stoppa AM, Royer B, Chaleteix C, Tiab M, Araujo C, Lenain P, Macro M, Voog E, Benboubker L, Allangba O, Jourdan E, Orsini-Piocelle F, Brechignac S, Eveillard JR, Belhadj K, Wetterwald M, Pegourie B, Jaccard A, Eisenmann JC, Glaisner S, Mohty M, Hulin C, Loiseau HA, Mathiot C, Attal M. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. Blood. 2018 Dec 13;132(24):2555-2563. Epub 2018 Oct 3. [http://www.bloodjournal.org/content/132/24/2555.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30282798 PubMed]

==Rd {{#subobject:d6803b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Rd: '''<u>R</u>'''evlimid (Lenalidomide) & low-dose '''<u>d</u>'''examethasone
<br>RevDex: '''<u>Rev</u>'''limid (Lenalidomide) & '''<u>Dex</u>'''amethasone
<br>Ld: '''<u>L</u>'''enalidomide & low-dose '''<u>d</u>'''examethasone
<br>LenDex: '''<u>L</u>'''enalidomide & '''<u>D</u>'''examethasone
===Variant #1, Len @ 25 mg 21/28 {{#subobject:107197|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1411321 Stewart et al. 2014 (ASPIRE)]
|style="background-color:#1a9851"|Phase III (C)
|[[#CRd_.28Carfilzomib.29|KRd]]
|style="background-color:#d73027"|Inferior OS (*)
|style="background-color:#d73027"|Inferior GHS/QoL
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1505654 Lonial et al. 2015 (ELOQUENT-2)]
|style="background-color:#1a9851"|Phase III (C)
|[[#ELd|ELd]]
|style="background-color:#fc8d59"|Seems to have inferior OS (*)
|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1516282 Moreau et al. 2016 (TOURMALINE-MM1)]
|style="background-color:#1a9851"|Phase III (C)
|[[#IRd|IRd]]
|style="background-color:#d73027"|Inferior PFS
|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1607751 Dimopoulos et al. 2016 (POLLUX)]
|style="background-color:#1a9851"|Phase III (C)
|[[#DRd|DRd]]
|style="background-color:#d73027"|Inferior PFS
|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500972/ Hou et al. 2017 (TOURMALINE-MM1 China Continuation)]
|style="background-color:#1a9851"|Phase III (C)
|[[#IRd|IRd]]
|style="background-color:#d73027"|Inferior OS
|
|-
|}
''Efficacy reported for '''ELOQUENT-2''' is based on the 2017 update. Efficacy reported for '''ASPIRE''' is based on the 2018 update.''
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
**'''POLLUX:''' Patients with CrCl of 30 to 60 mL/min/1.73m<sup>2</sup> received 10 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22
**'''POLLUX:''' Patients older than 75 years or underweight (BMI less than 18.5) could receive 20 mg

====Supportive medications====
''Best described by '''ASPIRE''':''
*[[Valacyclovir (Valtrex)]] (dose not specified) or equivalent [[:Category:Antivirals|antiviral]] while taking [[Lenalidomide (Revlimid)]]
*[[Aspirin]] (dose not specified) or other [[:Category:Anticoagulants|anticoagulant]] or [[:Category:Antiplatelet_agents|antiplatelet]] medication such as [[Clopidogrel (Plavix)]], [[:Category:Low_molecular_weight_heparins|low-molecular-weight heparin]] or [[Warfarin (Coumadin)]] while taking [[Lenalidomide (Revlimid)]]
*[[:Category:Bisphosphonates|Bisphosphonates]] while taking [[Dexamethasone (Decadron)]]
*[[Lansoprazole (Prevacid)]] (dose not specified) or other [[:Category:Proton_pump_inhibitors|proton pump inhibitor]] while taking [[Dexamethasone (Decadron)]]
*A prophylactic antibiotic ([[Ciprofloxacin (Cipro)]], [[Amoxicillin]], [[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] are given as examples)

'''28-day cycles'''

===Variant #2, Len @ 25 mg 21/28, with high-dose dex lead-in {{#subobject:60e23c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa070596 Weber et al. 2007 (MM-009)]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#Dexamethasone_monotherapy_3|Dexamethasone]]
|style="background-color:#91cf60"|Seems to have superior OS (*)
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa070594 Dimopoulos et al. 2007 (MM-010)]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#Dexamethasone_monotherapy_3|Dexamethasone]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
''Note: efficacy of '''MM-009''' is based on the 2009 pooled update.''
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 to 4: 40 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20 
**Cycle 5 onwards: 40 mg PO once per day on days 1 to 4

'''28-day cycles'''

===Variant #3, Len @ 30 mg 21/28 {{#subobject:94d1ca|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895441/ Richardson et al. 2006]
|style="background-color:#1a9851"|Randomized Phase II (E)
|Dexamethasone & twice-daily Lenalidomide
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''This regimen is essentially of historical interest.''
====Preceding treatment====
*[[#Lenalidomide_monotherapy|Lenalidomide]] x 2
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 30 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4, 15 to 18

'''28-day cycles'''

===Variant #4, Len @ 15 mg 21/28 ("RevLite") {{#subobject:f184d5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.14562/full Quach et al. 2017 (RevLite)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 15 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 to 4: 20 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20
**Cycle 5 onwards: 20 mg PO once per day on days 1 to 4

'''28-day cycles'''

===References===
# Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15;108(10):3458-64. Epub 2006 Jul 13. [http://www.bloodjournal.org/content/108/10/3458.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895441/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/16840727 PubMed]
# '''MM-010:''' Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007 Nov 22;357(21):2123-32. [https://www.nejm.org/doi/full/10.1056/NEJMoa070594 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18032762 PubMed]
## '''Update:''' Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009 Nov;23(11):2147-52. Epub 2009 Jul 23. [https://www.nature.com/leu/journal/v23/n11/full/leu2009147a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19626046 PubMed]
# '''MM-009:''' Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22;357(21):2133-42. [https://www.nejm.org/doi/full/10.1056/NEJMoa070596 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18032763 PubMed]
## '''Update:''' Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009 Nov;23(11):2147-52. Epub 2009 Jul 23. [https://www.nature.com/leu/journal/v23/n11/full/leu2009147a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19626046 PubMed]
# '''ASPIRE:''' Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 8;372(2):142-52. Epub 2014 Dec 6. [https://www.nejm.org/doi/full/10.1056/NEJMoa1411321 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25482145 PubMed]
## '''Subgroup analysis:''' Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016 Sep 1;128(9):1174-80. Epub 2016 Jul 20. [http://www.bloodjournal.org/content/128/9/1174.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009511/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27439911 PubMed]
## '''HRQoL analysis:''' Stewart AK, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A. Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol. 2016 Nov 10;34(32):3921-3930. [http://ascopubs.org/doi/full/10.1200/JCO.2016.66.9648 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27601539 PubMed]
## '''Update:''' Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018 Mar 10;36(8):728-734. Epub 2018 Jan 17. [http://ascopubs.org/doi/full/10.1200/JCO.2017.76.5032 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29341834 PubMed]
# '''ELOQUENT-2:''' Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015 Aug 13;373(7):621-31. [https://www.nejm.org/doi/full/10.1056/NEJMoa1505654 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26035255 PubMed]
## '''Update:''' Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017 Sep;178(6):896-905. Epub 2017 Jul 5. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14787/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28677826 PubMed]
## '''Update:''' Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018 Oct 15;124(20):4032-4043. Epub 2018 Sep 11. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.31680 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30204239 PubMed]
<!-- # '''Abstract:''' Philippe Moreau, MD, Tamás Masszi, MD, Norbert Grzasko, MD, PhD, Nizar J Bahlis, MD, Markus Hansson, Ludek Pour, MD, Irwindeep Sandhu, MD, Peter Ganly, BMBCh, PhD, Bartrum W Baker, MBChB, FRACP, FRCPA, Sharon Jackson, MBChB, FRACP, FRCPA, Anne-Marie Stoppa, MD, David R Simpson, MBChB, FRACP, FRCPA, Peter Gimsing, MD, DMSci, Antonio Palumbo, Laurent Garderet, MD, Michele Cavo, Shaji K. Kumar, MD, Cyrille Touzeau, MD, Francis Buadi, MD, Jacob P. Laubach, MD, Jianchang Lin, PhD, Deborah Berg, RN, MSN, Alessandra DiBacco, PhD, Ai-Min Hui, MD, PhD and Paul G. Richardson, MD. Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537). ASH Annual Meeting 2015 Abstract 727 [https://ash.confex.com/ash/2015/webprogram/Paper79829.html link to abstract] -->
# '''TOURMALINE-MM1:''' Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Apr 28;374(17):1621-1634. [https://www.nejm.org/doi/full/10.1056/NEJMoa1516282 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27119237 PubMed]
## '''Subgroup analysis:''' Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017 Dec 14;130(24):2610-2618. Epub 2017 Oct 20. [http://www.bloodjournal.org/content/130/24/2610.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29054911 PubMed]
# '''POLLUX:''' Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Oct 6;375(14):1319-1331. [https://www.nejm.org/doi/full/10.1056/NEJMoa1607751 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1607751/suppl_file/nejmoa1607751_protocol.pdf link to original protocol] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27705267 PubMed]
## '''Update:''' Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O' Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018 Dec;103(12):2088-96. Epub 2018 Sep 20. [https://www.ncbi.nlm.nih.gov/pubmed/30237262 PubMed]
# '''RevLite:''' Quach H, Fernyhough L, Henderson R, Corbett G, Baker B, Browett P, Blacklock H, Forsyth C, Underhill C, Cannell P, Trotman J, Neylon A, Harrison S, Link E, Swern A, Cowan L, Dimopoulos MA, Miles Prince H. Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. Br J Haematol. 2017 May;177(3):441-448. Epub 2017 Feb 15. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14562/full link to original article]'''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28197996 PubMed]
# '''TOURMALINE-MM1 China Continuation:''' Hou J, Jin J, Xu Y, Wu D, Ke X, Zhou D, Lu J, Du X, Chen X, Li J, Liu J, Gupta N, Hanley MJ, Li H, Hua Z, Wang B, Zhang X, Wang H, van de Velde H, Richardson PG, Moreau P. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. J Hematol Oncol. 2017 Jul 6;10(1):137. [https://jhoonline.biomedcentral.com/articles/10.1186/s13045-017-0501-4 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500972/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28683766 PubMed]

==Thal-Dex {{#subobject:13f920|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TD: '''<u>T</u>'''halidomide, '''<u>D</u>'''examethasone
<br>Thal-Dex: '''<u>Thal</u>'''idomide, '''<u>Dex</u>'''amethasone
===Variant #1, thalidomide 50->200 {{#subobject:518b17|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492844/ Hjorth et al. 2012 (NMSG 17/07)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Bortezomib_.26_Dexamethasone|Bort-Dex]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: this is an experimental arm that did not meet its primary endpoint; included here because it was eventually used to establish this regimen as a standard comparator.''
====Chemotherapy====
*[[Thalidomide (Thalomid)]] 50 mg PO once per day, increased by 50 mg every 3 weeks to a maximum of 200 mg PO once per day
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4

====Supportive medications====
*"Antithrombotic prophylaxis and acyclovir prophylaxis were not mandatory according to the study protocol but used routinely in an increasing proportion of participating centers during the study period."

'''21-day cycles until progression or best response, which would then be followed by 1 to 2 additional cycles'''

===Variant #2, thalidomide 200 {{#subobject:c91582|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/30/20/2475.long Garderet et al. 2012 (MMVAR/IFM 2005-04)]
|style="background-color:#1a9851"|Phase III (C)
|[[#VTD|VTD]]
|style="background-color:#d73027"|Inferior TTP
|-
|}
''Intended for patients who have relapsed after an autologous stem-cell transplant''
====Chemotherapy====
*[[Thalidomide (Thalomid)]] 200 mg PO once per day 
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4

====Supportive medications====
*[[Enoxaparin (Lovenox)]] 40 mg SC once per day for primary prophylaxis
*[[Warfarin (Coumadin)]] for secondary prophylaxis

'''21-day cycles for 12 months'''

===Variant #3, thalidomide 200->400 {{#subobject:4ea478|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://academic.oup.com/annonc/article/12/7/991/150672 Dimopoulos et al. 2001]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Thalidomide (Thalomid)]] 200 mg PO once per day for 14 days, then 400 mg PO once per day
*[[Dexamethasone (Decadron)]] as follows:
**Cycle 1: 20 mg PO once per day on days 1 to 4, 9 to 12, 17 to 20
**Subsequent cycles: 20 mg PO once per day on days 1 to 4

'''Monthly cycles'''
===References===
# Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, Vervessou E, Samantas E, Papadimitriou C, Economou O, Gika D, Panayiotidis P, Christakis I, Anagnostopoulos N. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol. 2001 Jul;12(7):991-5. [https://academic.oup.com/annonc/article/12/7/991/150672 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11521808 PubMed]
# '''NMSG 17/07:''' Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A; Nordic Myeloma Study Group (NMSG). Thalidomide and dexamethasone vs bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol. 2012 Jun;88(6):485-96. Epub 2012 Mar 30. [https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-0609.2012.01775.x link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492844/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22404182 PubMed]
<!-- Presented at the 37th Annual Meeting of the European Group for Blood and Marrow Transplantation, Paris, France, April, 3-6, 2011. -->
# '''MMVAR/IFM 2005-04:''' Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012 Jul 10;30(20):2475-82. Epub 2012 May 14. Erratum in: J Clin Oncol. 2012 Sep 20;30(27):3429. [http://jco.ascopubs.org/content/30/20/2475.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22585692 PubMed]

==VDC {{#subobject:d412fd|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VDC: '''<u>V</u>'''elcade (Bortezomib), '''<u>D</u>'''examethasone, '''<u>C</u>'''yclophosphamide 
<br>VCD: '''<u>V</u>'''elcade (Bortezomib), '''<u>C</u>'''yclophosphamide, '''<u>D</u>'''examethasone
<br>CyBorD: '''<u>Cy</u>'''clophosphamide, '''<u>Bor</u>'''tezomib, '''<u>D</u>'''examethasone
===Variant #1 {{#subobject:c1252d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://link.springer.com/article/10.1007%2Fs00277-017-3065-z Kropff et al. 2017 (CR015247)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Bortezomib_.26_Dexamethasone|VD]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Treatment details are from the [https://clinicaltrials.gov/show/NCT00813150 NCT record].''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
*[[Cyclophosphamide (Cytoxan)]] 50 mg PO once per day

'''21-day cycle for up to 8 cycles'''

===Variant #2 {{#subobject:f35a43|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13653/full de Waal et al. 2015]
|style="background-color:#91cf61"|Phase II
|-
|}
''Treatment intended for bortezomib-naive patients.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] as follows:
**Cycles 1 to 3: 1.3 mg/m<sup>2</sup> IV or SC once per day on days 1, 4, 8, 11
**Cycles 4 to 6: 1.6 mg/m<sup>2</sup> IV or SC once per day on days 1, 8, 15, 22
*[[Cyclophosphamide (Cytoxan)]] 50 mg PO once per day (continuous)
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 to 3: 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
**Cycles 4 to 6: 20 mg PO once per day on days 1, 2, 8, 9, 15, 16, 22, 23

====Supportive medications====
*Pneumococccal and anti-fungal prophylaxis "according to local protocols"
*[[Valacyclovir (Valtrex)]] (dose not specified) for herpes prophylaxis

'''21-day cycle for 3 cycles then 35-day cycle for 3 cycles'''
====Subsequent treatment====
*Patients with PR/CR: [[#Bortezomib_.26_Cyclophosphamide|Bortezomib & cyclophosphamide maintenance]]

===Variant #3 {{#subobject:d34841|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2007.06656.x/full Kropff et al. 2007]
|style="background-color:#91cf61"|Phase II
|-
|}

''Treatment intended for bortezomib-naive patients.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] as follows:
**Cycles 1 to 3: 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
**Cycles 4 to 6: 1.3 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22
*[[Cyclophosphamide (Cytoxan)]] 50 mg PO once per day (continuous)
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 to 3: 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
**Cycles 4 to 6: 20 mg PO once per day on days 1, 2, 8, 9, 15, 16, 22, 23

'''21-day cycle for 3 cycles then 35-day cycle for 3 cycles'''

===References===
# Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, Dechow T, Kröger N, Salwender H, Metzner B, Sezer O, Engelhardt M, Wolf HH, Einsele H, Volpert S, Heinecke A, Berdel WE, Kienast J; Deutsche Studiengruppe Multiples Myelom,. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol. 2007 Aug;138(3):330-7. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2007.06656.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17614819 PubMed]
# de Waal EG, de Munck L, Hoogendoorn M, Woolthuis G, van der Velden A, Tromp Y, Vellenga E, Hovenga S. Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients. Br J Haematol. 2015 Dec;171(5):720-5. Epub 2015 Sep 11. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13653/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26358087 PubMed]
# '''CR015247:''' Kropff M, Vogel M, Bisping G, Schlag R, Weide R, Knauf W, Fiechtner H, Kojouharoff G, Kremers S, Berdel WE. Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study. Ann Hematol. 2017 Nov;96(11):1857-1866. Epub 2017 Sep 14. [https://link.springer.com/article/10.1007%2Fs00277-017-3065-z link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28905189 PubMed]

==VTD {{#subobject:96881b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VTD: '''<u>V</u>'''elcade (Bortezomib), '''<u>T</u>'''halidomide, '''<u>D</u>'''examethasone

===Regimen {{#subobject:5ad72e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/30/20/2475.long Garderet et al. 2012 (MMVAR/IFM 2005-04)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Thal-Dex|TD]]
|style="background-color:#1a9850"|Superior TTP
|-
|}

''Intended for patients who have relapsed after an autologous stem-cell transplant''
====Chemotherapy====
*[[Bortezomib (Velcade)]] as follows:
**Cycles 1 to 8: 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11 of a 21-day cycle
**Cycles 9 to 12: 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 8, 15, 22 of a 42-day cycle
*[[Thalidomide (Thalomid)]] 200 mg PO once per day 
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4 of a 21-day cycle

====Supportive medications====
*[[Enoxaparin (Lovenox)]] 40 mg SC once per day for primary prophylaxis; [[Warfarin (Coumadin)]] for secondary prophylaxis
*Herpes zoster prophylaxis highly recommended

'''One year of treatment'''

===References===
<!-- Presented at the 37th Annual Meeting of the European Group for Blood and Marrow Transplantation, Paris, France, April, 3-6, 2011. -->
# '''MMVAR/IFM 2005-04:''' Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012 Jul 10;30(20):2475-82. Epub 2012 May 14. Erratum in: J Clin Oncol. 2012 Sep 20;30(27):3429. [http://jco.ascopubs.org/content/30/20/2475.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22585692 PubMed]

=Relapsed or refractory, non-randomized or retrospective data=

==BBD {{#subobject:adb507|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BBD: '''<u>B</u>'''endamustine, '''<u>B</u>'''ortezomib, '''<u>D</u>'''examethasone

===Regimen {{#subobject:cc2b7d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924931/ Ludwig et al. 2013 (AFAC BBD)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Bendamustine]] 70 mg/m<sup>2</sup> IV once per day on days 1 & 4
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] 20 mg (route not specified) once per day on days 1, 4, 8, 11

'''28-day cycle for up to 8 cycles'''

===References===
# '''AFAC BBD:''' Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, Greil R, Seebacher A, Pour L, Weißmann A, Adam Z. Bendamustine-bortezomib-dexamethasone is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood. 2014 Feb 13;123(7):985-91. Epub 2013 Nov 13. [http://www.bloodjournal.org/content/123/7/985.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924931/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24227817 PubMed]

==BLD {{#subobject:e8445|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BLD: '''<u>B</u>'''endamustine, '''<u>L</u>'''enalidomide, '''<u>D</u>'''examethasone

===Regimen {{#subobject:edc866|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392072/ Lentzsch et al. 2012]
|style="background-color:#91cf61"|Phase I/II
|-
|}

''Dosages listed are the determined maximally tolerated doses (MTD) of this phase I/II trial.''
====Chemotherapy====
*[[Bendamustine]] 75 mg/m<sup>2</sup> IV once per day on days 1 & 2
*[[Lenalidomide (Revlimid)]] 10 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] 40 mg (no route specified) once per week

====Supportive medications====
*[[Aspirin]] 325 mg PO once per day 
*"Gastroprotectant" ([[:Category:H2-receptor antagonists|H2-blocker]] or [[:Category:Proton pump inhibitors|PPI]])

'''28-day cycle for up to 8 cycles'''

===References===
<!-- Preliminary results were presented at the 53rd Annual Meeting of the American Society of Hematology, December 12, 2011, Orlando, FL. -->
# Lentzsch S, O'Sullivan A, Kennedy RC, Abbas M, Dai L, Pregja SL, Burt S, Boyiadzis M, Roodman GD, Mapara MY, Agha M, Waas J, Shuai Y, Normolle D, Zonder JA. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood. 2012 May 17;119(20):4608-13. Epub 2012 Mar 26. [http://www.bloodjournal.org/content/119/20/4608.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392072/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22451423 PubMed]

==Bortezomib-HyperCAD {{#subobject:00a88b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Bortezomib-HyperCAD: Bortezomib, '''<u>Hyper</u>'''fractionated '''<u>C</u>'''yclophosphamide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone
===Regimen {{#subobject:48e7e9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(16)30628-0/fulltext Saraceni et al. 2018]
|style="background-color:#ffffbe"|Retrospective
|-
|}
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1 & 4
*[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> IV every 12 hours on days 1 to 4 (8 doses; total dose per cycle: 2400 mg/m<sup>2</sup>)
*[[Doxorubicin (Adriamycin)]] 9 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 36 mg/m<sup>2</sup>)
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4

====Supportive Medications====
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 5 or 6
*[[Mesna (Mesnex)]] 350 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1
*Antiviral prophylaxis with [[Acyclovir (Valtrex)]] daily (dose not specified)
*"Most patients also received antifungal, antibacterial, and Pneumocysitc jiroveci pneumonia prophylaxis"

'''Duration of each cycle not specified; for most patients, treatment cycles were administered every 4 weeks'''

===References===
# '''Retrospective:''' Saraceni MM, Scott E, Maziarz RT, Siegel MB, Bassale S, Jiing S, Medvedova E. Modified hyperCVAD versus bortezomib-hyperCAD in patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e77-e84. [https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(16)30628-0/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29169873 PubMed]

==Bortezomib, Thalidomide, Dexamethasone, Panobinostat {{#subobject:6c61d0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:1bf613|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30165-X/fulltext Popat et al. 2016 (MUK-six)]
|style="background-color:#91cf61"|Phase I/II
|-
|}
''Note: this is the dose used in the phase II portion of the trial.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> SC once per day on days 1 & 8
*[[Thalidomide (Thalomid)]] 100 mg PO once per day
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1, 2, 8, 9
*[[Panobinostat (Farydak)]] 20 mg PO once per day on days 1, 3, 5, 8, 10, 12

'''21-day cycle for 16 cycles'''

===References===
# Popat R, Brown SR, Flanagan L, Hall A, Gregory W, Kishore B, Streetly M, Oakervee H, Yong K, Cook G, Low E, Cavenagh J; Myeloma UK Early Phase Clinical Trial Network.. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. Lancet Haematol. 2016 Dec;3(12):e572-e580. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30165-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27843120 PubMed]

==BTD {{#subobject:95a10c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BTD: '''<u>B</u>'''endamustine, '''<u>T</u>'''halidomide, '''<u>D</u>'''examethasone

===Regimen {{#subobject:57e4a5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13435/full Schey et al. 2015 (MUK''one'')]
|style="background-color:#1a9851"|Randomized Phase II (E)
|BTD with higher-dose benadmustine
|style="background-color:#d3d3d3"|See below
|-
|}
''This study involved two doses of bendamustine but the higher dose was too toxic, leading to premature closure. Note that while this study was randomized, it was "not powered to directly compare the two arms for statistically significant superiority." Dosage listed is the lower dose.''
====Chemotherapy====
*[[Bendamustine]] 60 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Thalidomide (Thalomid)]] 100 mg PO once per day on days 1 to 21 
**'''Note: abstract says days 1 to 21 but body of paper says days 1 to 28'''
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1, 8, 15, 22

====Supportive medications====
*Thromboprophylaxis (not specified) 
*Anti-infective prophylaxis (not specified)

'''28-day cycle for 6 to 9 cycles (2 cycles past best response)'''

===References===
# Schey S, Brown SR, Tillotson AL, Yong K, Williams C, Davies F, Morgan G, Cavenagh J, Cook G, Cook M, Orti G, Morris C, Sherratt D, Flanagan L, Gregory W, Cavet J; Myeloma UK Early Phase Clinical Trial Network. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial. Br J Haematol. 2015 Aug;170(3):336-48. Epub 2015 Apr 20. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13435/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25891006 PubMed]

==Carfilzomib & Panobinostat {{#subobject:9d99ab|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:69e42c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420216/ Berdeja et al. 2015]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] as follows:
**Cycle 1: 20 mg/m<sup>2</sup> IV once on days 1 & 2, then 45 mg/m<sup>2</sup> IV over 30 minutes once per day on days 8, 9, 15, 16
**Cycle 2 onwards: 45 mg/m<sup>2</sup> IV once per day on days 1, 2, 8, 9, 15, 16
*[[Panobinostat (Farydak)]] 30 mg PO once per day on days 1, 3, 5, 15, 17, 19
 
'''28-day cycles'''

===References===
# Berdeja JG, Hart LL, Mace JR, Arrowsmith ER, Essell JH, Owera RS, Hainsworth JD, Flinn IW. Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. Haematologica. 2015 May;100(5):670-6. Epub 2015 Feb 20. [http://www.haematologica.org/content/100/5/670 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420216/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25710456 PubMed]

==CPD {{#subobject:c7d038|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CPD: '''<u>C</u>'''arfilzomib, '''<u>P</u>'''omalidomide, '''<u>D</u>'''examethasone
<br>KPD: '''<u>K</u>'''yprolis (Carfilzomib), '''<u>P</u>'''omalidomide, '''<u>D</u>'''examethasone

===Regimen {{#subobject:1a0484|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643003/ Shah et al. 2015]
|style="background-color:#91cf61"|Phase I (*)
|-
|}
''Note, although this is described as a Phase I trial, an additional 20 patients were enrolled at the MTD, which is the dose reported here.''
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] as follows:
**Cycle 1: 20 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 2, then 27 mg/m<sup>2</sup> IV over 30 minutes once per day on days 8, 9, 15, 16
**Cycles 2 to 6: 27 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 2, 8, 9, 15, 16
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 to 4: 40 mg IV or PO once per day on days 1, 8, 15, 22
**Cycles 5 to 6: 20 mg IV or PO once per day on days 1, 8, 15, 22

====Supportive medications====
*"[[:Category:Antivirals|Anti-viral therapy]]"
*[[Aspirin]] 81 mg PO once per day 
**[[:Category:Low molecular weight heparins|Low molecular weight heparin]] was used in patients intolerant of aspirin 

'''28-day cycle for 6 cycles'''
====Subsequent treatment====
*[[#CPD_2|CPD maintenance]]

===References===
<!-- # '''Abstract:''' Jatin J. Shah, MD, Edward A. Stadtmauer, MD, Rafat Abonour, MD, Adam D. Cohen, MD, William I. Bensinger, MD, Cristina Gasparetto, MD, Jonathan L. Kaufman, MD, Suzanne Lentzsch, MD, Dan T. Vogl, MD, Robert Z. Orlowski, MD, PhD, Erica L. Kim, MPH, Marti McKinley, BSN, MBA, Brian G.M. Durie, MD. A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma. 2013 ASH Annual Meeting abstract 690. [http://www.myelomabeacon.com/resources/mtgs/ash2013/abs/690/ link to abstract] [http://myeloma.org/pdfs/Shah-74-3909.pdf link to presentation] '''contains verified protocol''' -->
# Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015 Nov 12;126(20):2284-90. Epub 2015 Sep 17. [http://www.bloodjournal.org/content/126/20/2284.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643003/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26384354 PubMed]

==CPR {{#subobject:cbf3b8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CPR: '''<u>C</u>'''yclophosphamide, '''<u>P</u>'''rednisone, '''<u>R</u>'''evlimid (Lenalidomide)
<br>REP: '''<u>R</u>'''evlimid (Lenalidomide), '''<u>E</u>'''ndoxan (Cyclophosphamide), '''<u>P</u>'''rednisone
===Variant #1, "REP" {{#subobject:ea6c95|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/128/19/2297.long Nijhof et al. 2016 (REPEAT)]
|style="background-color:#91cf61"|Phase I/II
|-
|}
''Details are for the MTD/phase II portion of the published phase I/II trial.''
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Cyclophosphamide (Cytoxan)]] 50 mg PO once per day
*[[Prednisone (Sterapred)]] 20 mg PO once per day

'''28-day cycles'''

===Variant #2, "CPR" {{#subobject:a8e16f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13100/full Reece et al. 2014]
|style="background-color:#91cf61"|Phase I/II
|-
|}

''Details are for the phase II portion of the published phase I/II trial.''
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> PO on days 1, 8, 15
*[[Prednisone (Sterapred)]] 100 mg PO once every other day
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21

'''28-day cycles'''

===References===
# Reece DE, Masih-Khan E, Atenafu EG, Jimenez-Zepeda VH, Anglin P, Chen C, Kukreti V, Mikhael JR, Trudel S. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma. Br J Haematol. 2015 Jan;168(1):46-54. Epub 2014 Aug 22. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13100/full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25146584 PubMed]
# Nijhof IS, Franssen LE, Levin MD, Bos GM, Broijl A, Klein SK, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Ypma PF, Raymakers R, van Spronsen DJ, Westerweel PE, Oostvogels R, van Velzen J, van Kessel B, Mutis T, Sonneveld P, Zweegman S, Lokhorst HM, van de Donk NW. Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. Blood. 2016 Nov;128(19), 2297-2306. Epub 2016 Sep 19. [http://www.bloodjournal.org/content/128/19/2297.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27647864 PubMed]

==CRD (Cyclophosphamide) {{#subobject:c9ad0a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CRD: '''<u>Cy</u>'''clophosphamide, '''<u>R</u>'''evlimid (Lenalidomide), '''<u>D</u>'''examethasone

===Regimen {{#subobject:81692e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2010.08250.x/full Schey et al. 2010]
|style="background-color:#91cf61"|Phase I/II
|-
|}
''This is the MTD of this phase I/II trial.''
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 600 mg PO once per day on days 1 & 8
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1 to 4, 8 to 11

====Supportive medications====
*[[Aspirin]] 75 mg PO once per day

'''28-day cycles'''

===References===
# Schey SA, Morgan GJ, Ramasamy K, Hazel B, Ladon D, Corderoy S, Jenner M, Phekoo K, Boyd K, Davies FE. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. Br J Haematol. 2010 Aug;150(3):326-33. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2010.08250.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20553268 PubMed]

==CTD {{#subobject:5d7a75|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CTD: '''<u>C</u>'''yclophosphamide, '''<u>T</u>'''halidomide, '''<u>D</u>'''examethasone

===Regimen {{#subobject:57a0c2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/15048060 Dimopoulos et al. 2004]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 150 mg/m<sup>2</sup> PO every 12 hours (before meals) on days 1 to 5
*[[Thalidomide (Thalomid)]] as follows:
**Cycles 1 to 3: 400 mg PO every evening on days 1 to 5 and 14 to 18
**Cycle 4 onwards: 400 mg PO every evening on days 1 to 5
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 to 3: 20 mg PO every morning after breakfast on days 1 to 5 and 14 to 18
**Cycle 4 onwards: 20 mg PO every morning after breakfast on days 1 to 5

'''28-day cycles'''

===References===
# Dimopoulos MA, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V, Poziopoulos C, Xilouri I, Zorzou MP, Anagnostopoulos N, Anagnostopoulos A. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J. 2004;5(2):112-7. [https://www.ncbi.nlm.nih.gov/pubmed/15048060 PubMed]

==Daratumumab monotherapy {{#subobject:d45aea|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:fc9461|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1506348 Lokhorst et al. 2015 (GEN501 part 2)]
|style="background-color:#91cf61"|Phase I/II
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext Lonial et al. 2016 (SIRIUS)]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: although '''SIRIUS''' was a randomized phase II trial, the randomization was to choose the dose for further assessment in an expansion cohort; the dose chosen (16 mg/kg from the start) is the one reported here:''
====Chemotherapy====
*[[Daratumumab (Darzalex)]] as follows:
**Weeks 1 to 8: 16 mg/kg IV once per week
**Weeks 9 to 24: 16 mg/kg IV once every 2 weeks
**Weeks 25 and on: 16 mg/kg IV once every 4 weeks
**Per the package insert, daratumumab infusion should complete within 15 hours. In Lokhorst et al. 2015, daratumumab was given over 8 hours.

====Supportive medications====
''This is a combination of what is listed in the daratumumab package insert and Lokhorst et al. 2015. There were protocol amendments in Lokhorst et al. 2015; listed medications are what was eventually used.''
*Prior to all daratumumab infusions:
**[[Methylprednisolone (Solumedrol)]] 100 mg IV prior to every dose of daratumumab. Per the package insert, after the second dose of daratumumab, dose may be reduced to 60 mg IV. Per Lokhorst et al. 2015, after the fourth dose of daratumumab, dose "could be reduced to 50 mg." 
**[[Acetaminophen (Tylenol)]] (paracetamol) 1000 mg (package insert: 650 to 1000 mg) PO 1 to 2 hours prior to daratumumab
**Antihistamine: [[Clemastine (Tavist)]] 1 mg IV, [[Cetirizine (Zyrtec)]] 10 mg PO, [[Diphenhydramine (Benadryl)]] 25 to 50 mg PO/IV, or equivalent 1 to 2 hours prior to daratumumab
*Post-treatment medications:
**[[Methylprednisolone (Solumedrol)]] 20 to 25 mg (package insert: 20 mg) PO or equivalent one and two days after every daratumumab infusion
**Package insert: "For patients with a history of obstructive pulmonary disorder, consider prescribing post-infusion medications such as short and long-acting bronchodilators, and inhaled corticosteroids."
*Package insert: "Initiate antiviral prophylaxis to prevent herpes zoster reactivation within 1 week of starting DARZALEX and continue for 3 months following treatment"

'''Given indefinitely'''

===References===
<!-- # '''Abstract:''' Plesner, Torben, Lokhorst, Henk, Gimsing, Peter, Nahi, Hareth, Lisby, Steen, Richardson, Paul G. Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study. ASH Annual Meeting Abstracts 2012 120: 73 [http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/73 link to abstract] -->
# '''GEN501:''' Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19. [https://www.nejm.org/doi/full/10.1056/NEJMoa1506348 link to original article] '''contains verified protocol''' [https://www.nejm.org/doi/full/10.1056/NEJMoa1506348/suppl_file/nejmoa1506348_appendix.pdf link to supplementary appendix] [https://www.nejm.org/doi/full/10.1056/NEJMoa1506348/suppl_file/nejmoa1506348_protocol.pdf link to study protocol] [https://www.ncbi.nlm.nih.gov/pubmed/26308596 PubMed]
## '''Pooled update:''' Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, Sasser AK, Axel A, Feng H, Uhlar CM, Wang J, Khan I, Ahmadi T, Nahi H. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016 Jul 7;128(1):37-44. Epub 2016 May 23. [http://www.bloodjournal.org/content/128/1/37.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937359/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27216216 PubMed]
<!-- # '''Abstract:''' Sagar Lonial, Brendan M. Weiss, Saad Zafar Usmani, Seema Singhal, Ajai Chari, Nizar J. Bahlis, Andrew Belch, Amrita Y. Krishnan, Robert A. Vescio, María-Victoria Mateos, Amitabha Mazumder, Robert Z. Orlowski, Heather J Sutherland, Joan Blade, Emma Catherine Scott, Huaibao Feng, Imran Khan, Clarissa M. Uhlar, Tahamtan Ahmadi, Peter Michael Voorhees. Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius). 2015 ASCO Annual Meeting abstract LBA8512. [http://meetinglibrary.asco.org/content/150339-156 link to abstract] -->
# '''SIRIUS:''' Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016 Apr 9;387(10027):1551-60. Epub 2016 Jan 7. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26778538 PubMed]
## '''Pooled update:''' Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, Sasser AK, Axel A, Feng H, Uhlar CM, Wang J, Khan I, Ahmadi T, Nahi H. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016 Jul 7;128(1):37-44. Epub 2016 May 23. [http://www.bloodjournal.org/content/128/1/37.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937359/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27216216 PubMed]

==DCEP {{#subobject:6dd02a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DCEP: '''<u>D</u>'''examethasone, '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''toposide, '''<u>P</u>'''latinol (Cisplatin)

===Variant #1 {{#subobject:bba45e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nature.com/bmt/journal/v28/n9/full/1703240a.html Lazzarino et al. 2001]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: this protocol is reported as a mobilization regimen prior to high dose autologous transplant; all patients had received prior therapy.''
====Chemotherapy====
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4
*[[Cyclophosphamide (Cytoxan)]] 400 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1600 mg/m<sup>2</sup>)
*[[Etoposide (Vepesid)]] 40 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 160 mg/m<sup>2</sup>)
*[[Cisplatin (Platinol)]] 10 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 40 mg/m<sup>2</sup>)

====Supportive medications====
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting 48 hours after chemotherapy and continuing through stem cell collection

'''One course'''

===Variant #2 {{#subobject:3b5550|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/17436400 Dadacaridou et al. 2007]
|style="background-color:#ffffbe"|Phase II, <20 patients reported
|-
|}
''These limited details are based on the abstract's description only. Full article was not available for review.''
====Chemotherapy====
*[[Dexamethasone (Decadron)]] 40 mg IV bolus once per day on days 1 to 4
*[[Cyclophosphamide (Cytoxan)]] 400 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1600 mg/m<sup>2</sup>)
*[[Etoposide (Vepesid)]] 40 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 160 mg/m<sup>2</sup>)
*[[Cisplatin (Platinol)]] 15 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 60 mg/m<sup>2</sup>)

====Supportive medications====
*[[Filgrastim (Neupogen) | G-CSF]] SC once per day, starting on day 5, to continue until neutrophil recovery

'''28-day cycles'''

===References===
# Lazzarino M, Corso A, Barbarano L, Alessandrino EP, Cairoli R, Pinotti G, Ucci G, Uziel L, Rodeghiero F, Fava S, Ferrari D, Fiumanò M, Frigerio G, Isa L, Luraschi A, Montanara S, Morandi S, Perego D, Santagostino A, Savarè M, Vismara A, Morra E. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant. 2001 Nov;28(9):835-9. [https://www.nature.com/bmt/journal/v28/n9/full/1703240a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11781643 PubMed] 
# Dadacaridou M, Papanicolaou X, Maltesas D, Megalakaki C, Patos P, Panteli K, Repousis P, Mitsouli-Mentzikof C. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. J BUON. 2007 Jan-Mar;12(1):41 to 4. [https://www.ncbi.nlm.nih.gov/pubmed/17436400 PubMed]

==DTPACE {{#subobject:e5c635|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DTPACE: '''<u>D</u>'''examethasone, '''<u>T</u>'''halidomide, '''<u>P</u>'''latinol (Cisplatin), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''toposide

===Regimen {{#subobject:02d8a9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/21/14/2732.long Lee et al. 2003]
|style="background-color:#91cf61"|Prospective
|-
|}
To be completed
====Chemotherapy====
*[[Dexamethasone (Decadron)]]
*[[Thalidomide (Thalomid)]]
*[[Cisplatin (Platinol)]]
*[[Doxorubicin (Adriamycin)]]
*[[Cyclophosphamide (Cytoxan)]]
*[[Etoposide (Vepesid)]]

===References===
# Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003 Jul 15;21(14):2732-9. Erratum in: J Clin Oncol. 2008 Apr 20;26(12): 2066. [http://jco.ascopubs.org/content/21/14/2732.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12860952 PubMed]

==FRD {{#subobject:69c2ac|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FRD: '''<u>F</u>'''arydak (Panobinostat), '''<u>R</u>'''evlimid (Lenalidomide), '''<u>D</u>'''examethasone
===Regimen {{#subobject:fe3761|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodadvances.org/content/1/19/1575 Chari et al. 2017]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Panobinostat (Farydak)]] 20 mg PO once per day on days 1, 3, 5, 15, 17, 19
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15

'''28-day cycles'''

===References===
# Chari A, Cho HJ, Dhadwal A, Morgan G, La L, Zarychta K, Catamero D, Florendo E, Stevens N, Verina D, Chan E, Leshchenko V, Laganà A, Perumal D, Mei AH, Tung K, Fukui J, Jagannath S, Parekh S. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Adv. 2017 Aug 21;1(19):1575-1583. eCollection 2017 Aug 22. [http://www.bloodadvances.org/content/1/19/1575 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728465/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29296798 PubMed]

==Hyper-CVAD {{#subobject:0df285|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Hyper-CVAD: '''<u>Hyper</u>'''fractionated '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone
===Variant #1 {{#subobject:62dcd6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1096-8652(199606)52:2%3C77::AID-AJH2%3E3.0.CO;2-2/abstract Dimopoulos et al. 1996]
|style="background-color:#91cf61"|Phase II
|-
|}
''To be completed.''
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]]
*[[Vincristine (Oncovin)]]
*[[Doxorubicin (Adriamycin)]]
*[[Dexamethasone (Decadron)]]

===Variant #2, modified {{#subobject:2fd9df|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(16)30628-0/fulltext Saraceni et al. 2018]
|style="background-color:#ffffbe"|Retrospective
|-
|}
''Note that vincristine is a flat dose.''
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> IV every 12 hours on days 1 to 4 (8 doses; total dose per cycle: 2400 mg/m<sup>2</sup>)
*[[Vincristine (Oncovin)]] 0.4 mg/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1.6 mg)
*[[Doxorubicin (Adriamycin)]] 9 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 36 mg/m<sup>2</sup>)
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4

====Supportive Medications====
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 5 or 6
*[[Mesna (Mesnex)]] 350 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1
*Antiviral prophylaxis with [[Valacyclovir (Valtrex)]] daily (dose not specified)
*"Most patients also received antifungal, antibacterial, and Pneumocysitc jiroveci pneumonia prophylaxis"

'''Duration of each cycle not specified; for most patients, treatment cycles were administered every 4 weeks'''

===References===
# Dimopoulos MA, Weber D, Kantarjian H, Delasalle KB, Alexanian R. HyperCVAD for VAD-resistant multiple myeloma. Am J Hematol. 1996 Jun;52(2):77-81. [https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1096-8652(199606)52:2%3C77::AID-AJH2%3E3.0.CO;2-2/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8638645 PubMed]
# '''Retrospective:''' Saraceni MM, Scott E, Maziarz RT, Siegel MB, Bassale S, Jiing S, Medvedova E. Modified hyperCVAD versus bortezomib-hyperCAD in patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e77-e84. [https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(16)30628-0/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29169873 PubMed]

==Ixazomib monotherapy {{#subobject:3fe8c1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, bi-weekly, 2 out of 3 weeks {{#subobject:b49446|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574453/ Richardson et al. 2014]
|style="background-color:#91cf61"|Phase I/II
|-
|}
''Note: this is the dosing used in the expansion cohort.''
====Chemotherapy====
*[[Ixazomib (Ninlaro)]] 2 mg/m<sup>2</sup> PO once per day on days 1, 4, 8, 11

'''21-day cycle for up to 12 cycles'''

===Variant #2, 3 out of 4 weeks {{#subobject:37950f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558585/ Kumar et al. 2015]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Ixazomib (Ninlaro)]] 5.5 mg PO once per day on days 1, 8, 15

'''28-day cycles''' 
====Subsequent treatment====
*Patients with no minor response by end of cycle 2, no PR by end of cycle 4, or progression: [[#Ixazomib_.26_Dexamethasone|Ixazomib & Dexamethasone]]

===References===
# Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014 Aug 14;124(7):1038-46. Epub 2014 Jun 11. [http://www.bloodjournal.org/content/124/7/1038.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574453/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24920586 PubMed]
# Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 2015 Aug 14;5:e338. [https://www.nature.com/bcj/journal/v5/n8/full/bcj201560a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558585/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26275080 PubMed]

==PAD {{#subobject:0f85ca|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PAD: '''<u>P</u>'''S-341 (Bortezomib), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone
<br>''Note that this regimen is sometimes called VAD but this can create a lot of confusion with the [[Multiple_myeloma_-_historical#VAD|"original" VAD which uses '''<u>V</u>'''incristine]].''
<br>VAD: '''<u>V</u>'''elcade (Bortezomib), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone

===Regimen {{#subobject:34e46e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70245-1/fulltext Cook et al. 2014 (NCRI Myeloma X Relapse)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
''Note: length of cycle is not reported in the manuscript, but presumably is 28 days, similar to other PAD regimens.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Doxorubicin (Adriamycin)]] 9 mg/m<sup>2</sup> IV once per day on days 1 to 4
**Could be given as a 4-day continuous infusion or as bolus injections
*[[Dexamethasone (Decadron)]] as follows:
**Cycle 1: 40 mg PO once per day on days 1 to 4, 8 to 11, 15 to 18
**Cycles 2 to 4: 40 mg PO once per day on days 1 to 4

'''2 to 4 cycles'''
====Subsequent treatment====
*[[#Melphalan.2C_then_auto_HSCT|High-dose melphalan & autologous hematopoietic cell transplant]] versus weekly oral cyclophosphamide maintenance

===References===
# '''NCRI Myeloma X Relapse:''' Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, Ashcroft AJ, Fletcher M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Chalmers A, O'Connor S, Drayson MT, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Jul;15(8):874-85. Epub 2014 Jun 16. Erratum in: Lancet Oncol. 2014 Aug;15(9):e365. Dosage error in article text. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70245-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24948586 PubMed]
## '''Update:''' Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Chown S, Heartin E, O'Connor S, Drayson MT, Hockaday A, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016 Jul;3(7):e340-51. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30049-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27374467 PubMed]

==PCP {{#subobject:c3aaf2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PCP: '''<u>P</u>'''omalidomide, '''<u>C</u>'''yclophosphamide, '''<u>P</u>'''rednisone

===Regimen {{#subobject:4a5941|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/122/16/2799.full Larocca et al. 2013]
|style="background-color:#91cf61"|Phase I/II
|-
|}

''Details are for the phase II portion of the published phase I/II trial.''
====Chemotherapy====
*[[Pomalidomide (Pomalyst)]] 2.5 mg PO once per day
*[[Cyclophosphamide (Cytoxan)]] 50 mg PO once every other day
*[[Prednisone (Sterapred)]] 50 mg PO once every other day

====Supportive medications====
*[[Aspirin]] 100 mg PO once per day or [[:Category:Low_molecular_weight_heparins|low-molecular-weight heparin]] "according to patient risk"

'''28-day cycle for 6 cycles'''
====Subsequent treatment====
*[[#Pomalidomide_.26_Prednisone|Pomalidomide & prednisone maintenance]]

===References===
# Larocca A, Montefusco V, Bringhen S, Rossi D, Crippa C, Mina R, Galli M, Marcatti M, La Verde G, Giuliani N, Magarotto V, Guglielmelli T, Rota-Scalabrini D, Omedé P, Santagostino A, Baldi I, Carella AM, Boccadoro M, Corradini P, Palumbo A. Pomalidomide, cyclophosphamide and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open label study. Blood. 2013 Oct 17;122(16):2799-806. Epub 2013 Aug 16. [http://www.bloodjournal.org/content/122/16/2799.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23954889 PubMed]

==Pomalidomide, Dexamethasone, Daratumumab {{#subobject:5538a8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:d6f1ac|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/130/8/974.long Chari et al. 2017 (EQUULEUS)]
|style="background-color:#91cf61"|Phase Ib
| style="background-color:#9ebcda" |ORR: 59% (95% CI, 49-69)
|-
|}
====Chemotherapy====
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] 40 mg PO once per week
**Patients older than 75 years or BMI less than 18.5: 20 mg PO once per week
*[[Daratumumab (Darzalex)]] as follows:
**Cycles 1 & 2: 16 mg/kg IV once per week
**Cycles 3 to 6: 16 mg/kg IV once every 2 weeks
**Cycle 7 onwards: 16 mg/kg IV once every 4 weeks

====Supportive medications====
*[[Dexamethasone (Decadron)]] 20 mg IV or PO prior to [[Daratumumab (Darzalex)]] infusions
**For patients receiving the 40 mg/wk dose, the remainder is given after the infusion on day of infusion
*[[Acetaminophen (Tylenol)]] prior to [[Daratumumab (Darzalex)]]
*An [[:Category:Antihistamines|antihistamine]] prior to [[Daratumumab (Darzalex)]]

'''28-day cycles'''

===References===
# '''EQUULEUS:''' Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017 Aug 24;130(8):974-981. Epub 2017 Jun 21. [http://www.bloodjournal.org/content/130/8/974.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28637662 PubMed]

==PVD {{#subobject:bf019d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PVD: '''<u>P</u>'''omalidomide, '''<u>V</u>'''elcade (Bortezomib), '''<u>D</u>'''examethasone

===Regimen {{#subobject:77f633|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5606008/ Paludo et al. 2017 (MC1082)]
|style="background-color:#91cf61"|Phase I/II
| style="background-color:#e0ecf4" |ORR: 86%
|-
|}
''This is the MTD used in the phase II portion of the trial.''
====Chemotherapy====
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV or SC once per day on days 1, 8, 15, 22
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22

====Supportive medications====
*[[Aspirin]] 325 mg PO once per day
**Full dose anticoagulation with [[:Category:Low molecular weight heparins|LMWH]] or [[Warfarin (Coumadin)]] could be substituted at physician discretion
*[[Acyclovir (Zovirax)]] or equivalent for VZV prophylaxis

'''28-day cycle for 8 cycles'''
====Subsequent treatment====
*Optionally, [[#Pomalidomide_monotherapy_2|pomalidomide maintenance]]

===References===
# '''MC1082:''' Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017 Sep 7;130(10):1198-1204. Epub 2017 Jul 6. [http://www.bloodjournal.org/content/130/10/1198.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5606008/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28684537 PubMed]

==RVD {{#subobject:3f1c8e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RVD: '''<u>R</u>'''evlimid (Lenalidomide), '''<u>V</u>'''elcade (Bortezomib), '''<u>D</u>'''examethasone
<br>VDR: '''<u>V</u>'''elcade (Bortezomib), '''<u>D</u>'''examethasone, '''<u>R</u>'''evlimid (Lenalidomide)
<br>VRD: '''<u>V</u>'''elcade (Bortezomib), '''<u>R</u>'''evlimid (Lenalidomide), '''<u>D</u>'''examethasone
<br>VRd: '''<u>V</u>'''elcade (Bortezomib), '''<u>R</u>'''evlimid (Lenalidomide), low-dose '''<u>d</u>'''examethasone
===Regimen {{#subobject:bf4291|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
|'''ORR'''
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123434/ Richardson et al. 2014]
|style="background-color:#91cf61"|Phase II
|64%
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 15 mg PO once per day on days 1 to 14
*[[Bortezomib (Velcade)]] 1 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
*[[Dexamethasone (Decadron)]] as follows:
**Cycles 1 to 4: 20 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12
**Cycles 5 to 8: 10 mg PO once per day on days 1, 2, 4, 5, 8, 9, 11, 12

====Supportive medications====
*[[Aspirin]] 81 mg or 325 mg PO once per day 
*[[:Category:Antivirals|Antiviral]] therapy for VZV prophylaxis

'''21-day cycle for 8 cycles'''
====Subsequent treatment====
*Patients with SD or better: [[#RVD_2|RVD maintenance]] at previously tolerated dose

===References===
# Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, Ghobrial IM, Schlossman RL, Munshi NC, Mazumder A, Vesole DH, Kaufman JL, Colson K, McKenney M, Lunde LE, Feather J, Maglio ME, Warren D, Francis D, Hideshima T, Knight R, Esseltine DL, Mitsiades CS, Weller E, Anderson KC. A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 6;123(10):1461-9. Epub 2014 Jan 15. [http://www.bloodjournal.org/content/123/10/1461.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123434/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24429336 PubMed]

==Thalidomide monotherapy {{#subobject:ff02e1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:43a4e3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199911183412102 Singhal et al. 1999]
|style="background-color:#91cf61"|Non-randomized
|-
|}
====Chemotherapy====
*[[Thalidomide (Thalomid)]] 200 mg PO once per day, increased by 200 mg every two weeks for six weeks, to final dose of 800 mg per day

'''Continued indefinitely'''

===References===
# Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999 Nov 18;341(21):1565-71. Erratum in: N Engl J Med 2000 Feb 3;342(5):364. [https://www.nejm.org/doi/full/10.1056/NEJM199911183412102 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10564685 PubMed]

==Vemurafenib monotherapy {{#subobject:c957e9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:5b6425|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971773/ Hyman et al. 2015 (VE-BASKET)]
|style="background-color:#ffffbe"|Basket trial, <20 pts in subgroup
|-
|}
''Note that Andrulis et al. 2013 is a single patient case report with a good response. Sharman et al. reports two patients with good response. In the Hyman et al. 2015 trial, there were 5 patients with multiple myeloma; "No patients with multiple myeloma have had a response to date."''
====Chemotherapy====
*[[Vemurafenib (Zelboraf)]] 960 mg PO twice per day

'''Continued indefinitely'''

===References===
# '''Case report:''' Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H, Neben K, Raab MS. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013 Aug;3(8):862-9. Epub 2013 Apr 23. [http://cancerdiscovery.aacrjournals.org/content/3/8/862.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23612012 PubMed]
# '''Case series:''' Sharman JP, Chmielecki J, Morosini D, Palmer GA, Ross JS, Stephens PJ, Stafl J, Miller VA, Ali SM. Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):e161-3. Epub 2014 Jun 11. [http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(14)00138-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24997557 PubMed]
# '''VE-BASKET:''' Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015 Aug 20;373(8):726-36. [https://www.nejm.org/doi/full/10.1056/NEJMoa1502309 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971773/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26287849 PubMed]

==VMPT {{#subobject:c7cda5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
VMPT: '''<u>V</u>'''elcade (Bortezomib), '''<u>M</u>'''elphalan, '''<u>P</u>'''rednisone, '''<u>T</u>'''halidomide

===Regimen {{#subobject:d55f41|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/109/7/2767.full Palumbo et al. 2007]
|style="background-color:#91cf61"|Phase I/II
|-
|}
''This is the MTD dosing of this phase I/II trial.''
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 15, 22
*[[Melphalan (Alkeran)]] 6 mg/m<sup>2</sup> PO once per day on days 1 to 5
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 5
*[[Thalidomide (Thalomid)]] 50 mg PO once per day on days 1 to 35

'''35-day cycle for 6 cycles'''

===References===
# Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V, Cangialosi C, Caravita T, Morabito F, Musto P, Bringhen S, Falco P, Avonto I, Cavallo F, Boccadoro M; Italian Multiple Myeloma Network; Gruppo Italiano Malattie Ematologicche dell'Adulto. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood. 2007 Apr 1;109(7):2767-72. [http://www.bloodjournal.org/content/109/7/2767.full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17148584 PubMed]

==ZRd {{#subobject:4e6061|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ZRd: '''<u>Z</u>'''olinza (Vorinostat), '''<u>R</u>'''evlimid (Lenalidomide), low-dose '''<u>d</u>'''examethasone
===Regimen {{#subobject:0c164a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.14429/abstract Sanchez et al. 2016]
|style="background-color:#91cf61"|Phase IIb
|-
|}
====Chemotherapy====
*[[Vorinostat (Zolinza)]] 400 mg PO once per day on days 1 to 7, 15 to 21
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22

'''28-day cycles'''

===References===
# Sanchez L, Vesole DH, Richter JR, Biran N, Bilotti E, McBride L, Anand P, Ivanovski K, Siegel DS. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens. Br J Haematol. 2017 Feb;176(3):440-447. Epub 2016 Nov 18. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14429/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27859001 PubMed]
<section end=rrmm />
<section begin=rrmm-consol />
=Consolidation after second-line therapy=

==Bortezomib monotherapy {{#subobject:bb5567|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:ba71b2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa043445 Richardson et al. 2005 (APEX)]
|style="background-color:#1a9851"|Phase III (E)
|[[Multiple_myeloma_-_historical#Dexamethasone_monotherapy_3|High-dose dexamethasone]]
|style="background-color:#91cf60"|Seems to have superior OS (*)
|-
|}
''Note: efficacy is reported based on the 2007 update.''
====Preceding treatment====
*[[#Bortezomib_monotherapy|Bortezomib induction]]
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

====Supportive medications====
*[[:Category:Bisphosphonates|Bisphosphonate]] IV therapy once every 3 to 4 weeks unless contraindicated

'''35-day cycle for 3 cycles'''

===References===
# '''APEX:''' Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005 Jun 16;352(24):2487-98. [https://www.nejm.org/doi/full/10.1056/NEJMoa043445 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15958804 PubMed]
## '''Subgroup analysis:''' Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Cowan JM, Anderson KC. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007 Jan;21(1):151-7. Epub 2006 Nov 9. [https://www.nature.com/articles/2404442 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17096017 PubMed]
## '''Update:''' Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San Miguel J, Bladé J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007 Nov 15;110(10):3557-60. Epub 2007 Aug 9. [http://www.bloodjournal.org/content/110/10/3557.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17690257 PubMed]

==Melphalan, then auto HSCT {{#subobject:149d91|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:83243a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70245-1/fulltext Cook et al. 2014 (NCRI Myeloma X Relapse)]
|style="background-color:#1a9851"|Phase III (E)
|Cyclophosphamide
|style="background-color:#91cf60"|Seems to have superior OS (*)
|-
|}
''Efficacy reported is based on the 2016 update.''
====Preceding treatment====
*[[#PAD|PAD]] x 4
====Preparative regimen====
*[[Melphalan (Alkeran)]] 200 mg/m<sup>2</sup> IV on day -2

'''Stem cells re-infused on day 0'''

===References===
# '''NCRI Myeloma X Relapse:''' Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, Ashcroft AJ, Fletcher M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Chalmers A, O'Connor S, Drayson MT, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Jul;15(8):874-85. Epub 2014 Jun 16. Erratum in: Lancet Oncol. 2014 Aug;15(9):e365. Dosage error in article text. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70245-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24948586 PubMed]
## '''Update:''' Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Chown S, Heartin E, O'Connor S, Drayson MT, Hockaday A, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016 Jul;3(7):e340-51. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30049-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27374467 PubMed]

=Maintenance after second-line therapy=

==Bortezomib monotherapy {{#subobject:2c45eb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:366c79|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737504/ Orlowski et al. 2015]
|style="background-color:#1a9851"|Randomized Phase II (C)
|Bortezomib & Siltuximab
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Preceding treatment====
*[[#Bortezomib_monotherapy|Bortezomib induction]]
====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

'''35-day cycles'''
===References===
# Orlowski RZ, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, Goranova-Marinova V, Dimopoulos MA, Cavenagh JD, Špička I, Maiolino A, Suvorov A, Bladé J, Samoylova O, Puchalski TA, Reddy M, Bandekar R, van de Velde H, Xie H, Rossi JF. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol. 2015 Jan;90(1):42-9. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737504/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25294016 PubMed]

==Bortezomib & Cyclophosphamide {{#subobject:eaadfe|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:5e9a21|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13653/full de Waal et al. 2015]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#VDC|VDC]] x 6

====Chemotherapy====
*[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV or SC once on day 1
*[[Cyclophosphamide (Cytoxan)]] 50 mg PO once per day

====Supportive medications====
*Pneumococccal and anti-fungal prophylaxis "according to local protocols"
*[[Valacyclovir (Valtrex)]] (dose not specified) for herpes prophylaxis

'''14-day cycle for up to 1 year'''

===References===
# de Waal EG, de Munck L, Hoogendoorn M, Woolthuis G, van der Velden A, Tromp Y, Vellenga E, Hovenga S. Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients. Br J Haematol. 2015 Dec;171(5):720-5. Epub 2015 Sep 11. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13653/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26358087 PubMed]

==CPD {{#subobject:bfa533|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CPD: '''<u>C</u>'''arfilzomib, '''<u>P</u>'''omalidomide, '''<u>D</u>'''examethasone
<br>KPD: '''<u>K</u>'''yprolis (Carfilzomib), '''<u>P</u>'''omalidomide, '''<u>D</u>'''examethasone

===Regimen {{#subobject:edd05b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643003/ Shah et al. 2015]
|style="background-color:#91cf61"|Phase I (*)
|-
|}
''Note, although this is described as a Phase I trial, an additional 20 patients were enrolled at the MTD, which is the dose reported here.''
====Preceding treatment====
*[[#CPD|CPD]] x 6
====Chemotherapy====
*[[Carfilzomib (Kyprolis)]] 27 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 2, 15, 16
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21
*[[Dexamethasone (Decadron)]] 20 mg IV or PO once per day on days 1, 8, 15, 22

====Supportive medications====
*"[[:Category:Antivirals|Anti-viral therapy]]"
*[[Aspirin]] 81 mg PO once per day 
**[[:Category:Low molecular weight heparins|Low molecular weight heparin]] was used in patients intolerant of aspirin 

'''28-day cycles'''

===References===
<!-- # '''Abstract:''' Jatin J. Shah, MD, Edward A. Stadtmauer, MD, Rafat Abonour, MD, Adam D. Cohen, MD, William I. Bensinger, MD, Cristina Gasparetto, MD, Jonathan L. Kaufman, MD, Suzanne Lentzsch, MD, Dan T. Vogl, MD, Robert Z. Orlowski, MD, PhD, Erica L. Kim, MPH, Marti McKinley, BSN, MBA, Brian G.M. Durie, MD. A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma. 2013 ASH Annual Meeting abstract 690. [http://www.myelomabeacon.com/resources/mtgs/ash2013/abs/690/ link to abstract] [http://myeloma.org/pdfs/Shah-74-3909.pdf link to presentation] '''contains verified protocol''' -->
# '''Phase I:''' Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015 Nov 12;126(20):2284-90. Epub 2015 Sep 17. [http://www.bloodjournal.org/content/126/20/2284.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643003/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26384354 PubMed]

==Daratumumab monotherapy {{#subobject:05dc39|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:05fb0a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1606038 Palumbo et al. 2016 (CASTOR)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#DVd|DVd]] x 8
====Chemotherapy====
*[[Daratumumab (Darzalex)]] 16 mg/kg IV once on day 1

'''28-day cycles'''

===References===
<!-- # ASCO 2016 Abstract LBA4 -->
# '''CASTOR:''' Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66. [https://www.nejm.org/doi/full/10.1056/NEJMoa1606038 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1606038/suppl_file/nejmoa1606038_appendix.pdf link to supplementary appendix] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27557302 PubMed]
## '''Update:''' Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018 Dec;103(12):2079-87. Epub 2018 Sep 20. [http://www.haematologica.org/content/103/12/2079 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30237264 PubMed]

==Pomalidomide monotherapy {{#subobject:5d4f4d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a3138c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
|'''ORR'''
|-
|[http://www.bloodjournal.org/content/130/10/1198.long Paludo et al. 2017]
|style="background-color:#91cf61"|Phase I/II
|86%
|-
|}
====Preceding treatment====
*[[#PVD|PVD]] x 8
====Chemotherapy====
*[[Pomalidomide (Pomalyst)]] 4 mg PO once per day on days 1 to 21

====Supportive medications====
*[[Aspirin]] 325 mg PO once per day
**Full dose anticoagulation with [[:Category:Low molecular weight heparins|LMWH]] or [[Warfarin (Coumadin)]] could be substituted at physician discretion
*[[Acyclovir (Zovirax)]] or equivalent for VZV prophylaxis

'''28-day cycles'''

===References===
# Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017 Sep 7;130(10):1198-1204. Epub 2017 Jul 6. [http://www.bloodjournal.org/content/130/10/1198.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28684537 PubMed]

==Pomalidomide & Prednisone {{#subobject:519843|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:171099|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
|'''ORR'''
|-
|[http://www.bloodjournal.org/content/122/16/2799.full Larocca et al. 2013]
|style="background-color:#91cf61"|Phase I/II
|51%
|-
|}
''Details are for the phase II portion of the published phase I/II trial.''
====Preceding treatment====
*[[#PCP|PCP]] x 6
====Chemotherapy====
*[[Pomalidomide (Pomalyst)]] 1 mg PO once per day
*[[Prednisone (Sterapred)]] 25 mg PO once every other day

====Supportive medications====
*[[Aspirin]] 100 mg PO once per day or [[:Category:Low_molecular_weight_heparins|low-molecular-weight heparin]] "according to patient risk"

'''Continued indefinitely'''

===References===
# Larocca A, Montefusco V, Bringhen S, Rossi D, Crippa C, Mina R, Galli M, Marcatti M, La Verde G, Giuliani N, Magarotto V, Guglielmelli T, Rota-Scalabrini D, Omedé P, Santagostino A, Baldi I, Carella AM, Boccadoro M, Corradini P, Palumbo A. Pomalidomide, cyclophosphamide and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open label study. Blood. 2013 Oct 17;122(16):2799-806. Epub 2013 Aug 16. [http://www.bloodjournal.org/content/122/16/2799.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23954889 PubMed]

==RVD {{#subobject:fe8a85|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RVD: '''<u>R</u>'''evlimid (Lenalidomide), '''<u>V</u>'''elcade (Bortezomib), '''<u>D</u>'''examethasone
<br>VDR: '''<u>V</u>'''elcade (Bortezomib), '''<u>D</u>'''examethasone, '''<u>R</u>'''evlimid (Lenalidomide)
<br>VRD: '''<u>V</u>'''elcade (Bortezomib), '''<u>R</u>'''evlimid (Lenalidomide), '''<u>D</u>'''examethasone
<br>VRd: '''<u>V</u>'''elcade (Bortezomib), '''<u>R</u>'''evlimid (Lenalidomide), low-dose '''<u>d</u>'''examethasone
===Regimen {{#subobject:0c163e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123434/ Richardson et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#RVD|Salvage RVD]]
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] (at previously tolerated dose) PO once per day on days 1 to 14
*[[Bortezomib (Velcade)]] (at previously tolerated dose) IV once per day on days 1 & 8
*[[Dexamethasone (Decadron)]] 10 mg PO once per day on days 1, 2, 8, 9

====Supportive medications====
*[[Aspirin]] 81 mg or 325 mg PO once per day 
*[[:Category:Antivirals|Antiviral]] therapy for VZV prophylaxis

'''21-day cycles'''

===References===
# Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, Ghobrial IM, Schlossman RL, Munshi NC, Mazumder A, Vesole DH, Kaufman JL, Colson K, McKenney M, Lunde LE, Feather J, Maglio ME, Warren D, Francis D, Hideshima T, Knight R, Esseltine DL, Mitsiades CS, Weller E, Anderson KC. A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 6;123(10):1461-9. Epub 2014 Jan 15. [http://www.bloodjournal.org/content/123/10/1461.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123434/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24429336 PubMed]
<section end=rrmm-consol />
{{#lst:Multiple myeloma|bottom}}
[[Category:Multiple myeloma regimens]]
[[Category:Disease-specific pages]]
[[Category:Plasma cell dyscrasias]]
